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 Abstract 
The rational design of an HIV-1 vaccine immunogen able to induce potent, cross-
reactive, neutralising antibodies remains one of the single greatest challenges in the 
field of vaccine research today.  Roughly a dozen broadly neutralising monoclonal 
antibodies have been isolated to date, and their epitopes represent important 
vaccination targets.  Interestingly, apart from three that identify over-lapping epitopes 
in gp41, all of the broadly neutralising monoclonal antibodies target epitopes apparent 
on different conformations of gp120 (including the epitopes of PG9/PG16).  Thus the 
gp120 monomer remains the most ideal template for immunogen design.  Recently, 
epitopes in the C3-V4 region of gp120 have been shown to be major targets for early 
strain-specific neutralising antibodies in subtype C infected individuals.  Autologous 
neutralising antibodies identify vulnerable sites on the envelope, and understanding 
the nature of antigenic “hotspots” on gp120 will help to guide rational vaccine design.  
This study sought to confirm in four individuals that the C3-V4 epitope was in fact 
apparent on monomeric gp120, and thereafter to better characterise the nature of viral 
escape from these antibodies.  Using magnetic beads coated with one of 16 different 
recombinant gp120 proteins it was confirmed that the C3-V4 response was aimed at a 
monomer-specific epitope in all four cases.  In two instances these antibodies were 
shown to contribute to autologous neutralisation, while in a third the existence of 
quaternary structure specific antibodies that could not be adsorbed with monomeric 
gp120 made this link impossible.  In the forth instance transfer of the C3-V4 region 
was shown to expose a normally occluded epitope in the CD4 binding site.  This 
research also provided evidence for other epitopes for autologous neutralising 
antibodies in C3, overlapping with the CD4 binding site and V5.  Lastly, by 
introducing relevant escape mutations into the parental recombinant gp120s and then 
comparing the ability of these proteins to adsorb out anti-C3 antibodies, it was shown 
that while these mutations conferred complete resistance to neutralisation they did not 
prevent the antibodies from binding to their respective epitopes.  The extensive 
characterisation of C3-related epitopes such as those described in this research should 
no doubt contribute to the rational design of a gp120 based vaccine immunogen aimed 
at eliciting broad and potent neutralising antibody responses.   
 1 
Chapter One: Introduction 
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Although the HIV/AIDS epidemic appears to be stabilising, recent statistics released 
by the World Health Organisation still counts approximately 33 million people living 
with HIV across the globe as of 2008.  Two thirds of these people are located in sub-
Saharan Africa and an astonishing 17% (5.7 million people) live in the Republic of 
South Africa (Joint United Nations Programme on HIV/AIDS and World Health 
Organization, 2009).  Every year roughly three million people are infected with HIV 
and two million people die from AIDS related illnesses.  Although efficient 
antiretroviral programmes are dramatically increasing the life expectancy of HIV-
infected people, an effective means for preventing the spread of infection is not yet 
generally available.  After a recent trial conducted in South Africa, the success of an 
intra-vaginally applied microbicide gel in preventing infection was reported (Abdool 
Karim et al., 2010).  No doubt with much more research, microbicide gels will afford 
a valuable means with which to control infection.  However a microbicide gel serves 
only as a single barrier and once an HIV virion has crossed the mucosa it is no longer 
effective.  Also the success of such a product correlates significantly with strict 
adherence.  Pre-exposure chemoprophylaxis is another prevention strategy shown to 
significantly reduce transmission rates in people at high risk for HIV infection (Grant 
et al., 2010).  However this strategy is also dependent on strict adherence, and may 
further compound the problem of drug resistance for people already on anti-retroviral 
treatment.  A vaccine able to induce a potent immune response offers a far more 
practical solution to the HIV/AIDS epidemic.  Once a target cell is infected, the virus 
integrates into the host’s genome and sets up a viral reservoir which serves as a 
constant source of new viruses.  To successfully clear this infection, vaccination may 
need to induce both neutralising antibodies and an effective cytotoxic immune cell 
response (Bramwell and Perrie, 2005).  It is of potential significance though that most 
antiviral vaccines today work primarily by inducing neutralising antibodies (Pantaleo 
and Koup, 2004).  In fact promising work in macaques has shown that the passive 
transfer of neutralising antibodies is able to block infection by chimeric SIV-HIV 
viruses (Mascola et al., 2000; Parren et al., 2001).  However the elicitation of broadly 
cross-reactive neutralising antibodies has proven to be a daunting task, both in natural 
infection and after conventional vaccination strategies.  Resolving the structure of the 
HIV envelope glycoprotein sub-units and their interaction with neutralising antibodies 
has helped researchers to understand some of the requirements for a good vaccine 
immunogen (Calarese et al., 2003; Song et al., 2009; Zhou et al., 2010; Zhou et al., 
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2007).  Unfortunately much is still unknown about the nature of accessible, 
immunogenic epitopes on the envelope surface.  This is even further compounded by 
subtype specific differences in HIV antigenicity (Gnanakaran et al., 2007).  Although 
there are at least nine different viral subtypes, clade C is the most predominant and 
accounts for roughly half of all global infections (Hemelaar et al., 2006).  This is 
largely due to the fact that subtype C makes up the majority of infections in the 
world’s most heavily burdened countries in sub-Saharan Africa and sub-Central Asia.  
As a consequence the South African population is an ideal research base from which 
to study the diverse viral antigenicity and subsequent host responses generated by one 
of the largest epidemics in modern history.   
HIV-1 Envelope Glycoprotein Synthesis 
The envelope glycoprotein is preceded by a long (approximately thirty amino acids) 
hydrophobic signal peptide with a short polar N-terminal cap (Wain-Hobson et al., 
1985).  The signal peptide is responsible for co-translational translocation of the 
envelope glycoprotein into the rough endoplasmic reticulum.  It is then cleaved off 
from the final protein structure (Ellerbrok et al., 1992).  The secreted glycoprotein is 
covered by approximately 30 potential N-linked glycans that make up a third of its 
160 kDa net weight (Geyer et al., 1988; Wain-Hobson et al., 1985).  These glycans 
are added during translation and are important for proper folding of the envelope 
glycoprotein (Land, Zonneveld, and Braakman, 2003).  They are almost exclusively 
oligomannose in structure, with a low proportion being processed further to complex 
glycans (Geyer et al., 1988).  Once properly folded and glycosylated, the envelope 
glycoprotein is transported to the Golgi complex and cleaved by host cellular 
proteases to yield non-covalently associated gp120-gp41 dimers (Stein and Engleman, 
1990).  The pro-protein convertases and in particular the serine protease furin are 
implicated in recognition and processing of the gp120-gp41 cleavage motif R-X-K/R-
R (Moulard and Decroly, 2000).  The gp41 monomer is membrane embedded and 
contains the membrane fusing machinery (Chan et al., 1997).  Trimeric complexes 
consisting of three gp41 and three gp120 non-covalently linked sub-units localise to 
lipid rafts on the host membrane, which serve as the sites for viral assembly and 
eventual budding of nascent virions (Campbell, Crowe, and Mak, 2001).  The 
glycoprotein trimeric complex represents the sole target for neutralising antibodies.   
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Structure of the gp120 monomer 
Population sequence analysis traditionally divides the HIV-1 envelope gene into five 
conserved regions (Figure 1A) separated by five interjecting variable regions (Figure 
1B) (Modrow et al., 1987).  Within the conserved gp120 amino acid sequence are 
usually nine disulphide bonds, and four of these cystine pairs traditionally define the 
stems of variable loops V1, V2, V3, and V4 (Leonard et al., 1990).  However there 
exist inter-clade structural differences such an additional disulphide bond found in the 
V4 loop of CRF_AE (McCutchan et al., 1996; Mokili et al., 2002; Trkola et al., 
1995).   
 
The crystal structure of gp120 derived from several strains has been elucidated in 
complex with a soluble CD4 receptor and various co-receptor binding site directed 
monoclonal antibody fragments (Diskin, Marcovecchio, and Bjorkman, 2010; Huang 
et al., 2007; Huang et al., 2005; Kwong et al., 1998; Pancera et al., 2010a).  Crystal 
structures of gp120 have also been obtained in complex with various anti-CD4 
binding site antibodies (Chen et al., 2009; Zhou et al., 2010; Zhou et al., 2007).  In 
addition the crystal structure of an unliganded SIVmac gp120 has also been determined 
(Chen et al., 2005).  To facilitate crystal formation these structures lack the hyper-
variable V1-V2 domain, and in most instances portions of the N-terminal and C-
terminal ends and V3 loop.  However, overall they divide the gp120ΔV1-V2 core into 
three conserved structural domains (Figure 1C).  These are the inner, outer, and 
bridging sheet domains (Kwong et al., 1998).  The outer domain is the most solvent 
exposed in the context of the trimer and forms the primary neutralisation determinant 
on gp120 (Zhou et al., 2007).  The inner domain is highly conserved and represents 
the region of gp120 that is shielded from solvent at the trimer interface.  The bridging 
sheet is composed of elements in C1, C2, and C4, forming a mini domain that makes 
up part of the CD4 and co-receptor binding sites.  A recent crystal structure was the 
first to include the N- and C- terminal structures (Figure 1D).  These 79 amino acids 
define a previously unidentified seven stranded β-sandwich containing predominantly 
gp41 contacting residues (Pancera et al., 2010a).  This structurally invariant region 
provides an immobile face for gp120-gp41 non-covalent interactions.  In contrast by 
comparing the liganded and unliganded structures it seems that radically different 
conformations are possible in the inner domain (Figures 2).   
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Figure 1: Structure of the HIV-1 envelope glycoprotein sub-unit gp120 
(A) A linear schematic of the HIV-1 envelope sequence is shown where the conserved regions C1-C5 are indicated in maroon, and interjecting variable sequences V1-V2, V3, V4, and 
V5 are shown in pink, red, purple, and blue respectively.  The location and secondary structure of each of the conserved regions within the gp120 molecule are indicated by ribbon 
diagrams.  That part of the sequence that makes up the inner domain (green), outer domain (orange), the V1-V2 domain (grey), or the bridging sheet (black) is indicated by coloured 
circles.  (B) Ribbon diagram showing the location of variable loop structures on the gp120 molecule, coloured as in (A).  (C) Sub-domain structure of the gp120 monomer is shown and 
coloured as in (A).  (D) Ribbon diagram depicting the layered topology of the gp120 molecule.  Layers one, two, and three are coloured cyan, green, and orange respectively.  Protein 
structure images for this and all subsequent figures (unless otherwise stated) were created from the superimposed pdb files 2B4C and 3JWD using Swiss-PdbViewer programme (Guex 
and Peitsch, 1997) and Pymol (DeLano, W.L. The PyMOL Molecular Graphics System (2002) DeLano Scientific, San Carlos, CA, USA (http://www.pymol.org).  
A 
B C D 
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Of course the unliganded SIV gp120 core has a greater conformational freedom and 
the crystal structure that was resolved may not reflect the native conformation of the 
HIV-1 gp120 protein monomer.  Nevertheless it implies that multiple conformations 
are possible within a single gp120 monomer, and these rearrangements potentially 
mask the receptor binding sites (Chen et al., 2005).  From the seven stranded beta 
sandwich three topological layers extent outward by means of flexible loop structures.  
Layers one and two of the inner domain serve to stabilise the CD4 bound 
conformation through extensive aromatic hydrophobic packing interactions (Kassa et 
al., 2009).  Surprisingly many of the amino acids that are important for stabilisation of 
the envelope oligomer are found in the layer two associated alpha helix, which is not 
surface exposed in the CD4 bound conformation (Finzi et al., 2010).  In addition this 
alpha helix displays the greatest conformational plasticity between liganded crystal 
structures (Chen et al., 2009).  Therefore current thinking implicates layer two as the 
primary structure involved in the refolding of gp120 between liganded and unliganded 
conformations.   
 
 
 
Figure 2: Conformational plasticity of the inner domain of gp120 
The liganded crystal structure of the HIV-1 gp120 molecule is shown on the left, while the unliganded 
SIV gp120 is shown on the right.  The outer domain is coloured grey, while the inner domain is in 
multi-colours.  C1 is coloured blue, β2 and β3 of the bridging sheet are coloured green, elements of the 
inner domain in C2 are coloured orange, while those in C5 are coloured red.  The crystal structure of 
the SIV gp120 core has a truncation of the V3 loop not present in the HIV liganded structure.  Figures 
were created from the pdb files 2B4C and 2BF1.   
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The CD4 binding site 
The crystal structure of HIV-1HXB2 in complex with soluble CD4 has mapped the CD4 
binding site to a complex, discontinuous surface on gp120 (Kwong et al., 1998).  CD4 
contact residues reside in conserved regions of the bridging sheet domain, C2, C3, C5, 
and the stem of V5 (Figure 3).  By scattering contact residues between several mobile 
secondary structures, binding of the host CD4 receptor to gp120 results in an 
unfavourable entropy (-TΔS) change of 44.2 kcal/mol (Kwong et al., 2002).  It is the 
highly specific nature of the interface and thus the highly favourable enthalpy of 
binding (-54.62 kcal/mol) that renders the interaction feasible.  While the average 
contribution of entropy for standard antibody-protein interactions is approximately 7 
kcal/mol, the average entropy of binding for CD4 binding site directed antibodies is 
23.1 kcal/mol (Kwong et al., 2002).  This means that potential neutralising antibodies 
targeting the CD4 binding site must have significantly favourable enthalpies to 
compensate for gp120 reorganisation.  The CD4 binding site is further protected from 
antibodies by its occlusion both in monomeric gp120 and the native trimer.  The 
contact surface exists in a crevice between the inner and outer domains.  At the base 
of this recession a hydrophobic pocket is formed, and its interaction with Phe
43
 at the 
distal most tip of CD4 is crucial to favourable binding (Kwong et al., 1998).  On the 
native trimer the large V1-V2 loop and an array of flexible glycans have been 
implicated in occluding the CD4 binding site (Binley et al., 2010; Pinter et al., 2004; 
Wyatt et al., 1995; Zhu et al., 2001).  Despite these defence mechanisms almost all 
HIV-1 infected individuals develop antibodies that target the CD4 binding site of 
gp120, but most possess limited or no neutralisation potential (Gray et al., 2009).  The 
epitopes for these antibodies are not accessible on the native trimer, and these B-cell 
specificities are probably induced by less constrained conformations of monomeric 
gp120 released into the blood from cellular debris or shed from the virus surface.   
The co-receptor binding site 
In addition to CD4, HIV-1 must also directly bind to a chemokine receptor such as 
CCR5 or CXCR4 in order to efficiently infect host cells.  The binding of gp120 to co-
receptors occurs via a separate discontinuous region to CD4 attachment however, the 
conformational rearrangements induced by CD4 are an essential precursor to this 
interaction (Lapham et al., 1999; Trkola et al., 1996; Wu et al., 1996).  The co-
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receptor binding site is thus similar to the CD4 binding site in that it is composed of 
multiple mobile regions of gp120 protected by a conformational mask (Figure 3).  
Residues that interact with the co-receptor are found around the bridging sheet, C4, 
and V3 (Cormier et al., 2001; Rizzuto and Sodroski, 2000; Rizzuto et al., 1998).  The 
V3 loop is highly immunogenic and HIV infected individuals often develop high titre 
antibodies to this region, but these are only capable of neutralising laboratory adapted 
isolates because the V3 epitope is occluded on primary isolates by the V1-V2 domain 
(Krachmarov et al., 2005; Pinter et al., 2004; Zhu et al., 2001).  Reorganisation of 
trimeric gp120 following CD4 docking re-orientates the V3 loops in a drastically 
exposed conformation toward the host membrane allowing the V3 crown to bind the 
second extracellular loop of CCR5 (Huang et al., 2005).  CD4 independent isolates 
have been isolated in vitro that constitutively present an exposed co-receptor binding 
site and are thus highly neutralisation sensitive (Kolchinsky et al., 2001).  Thus it 
seems that CD4 dependence may have evolved as a mechanism to protect the co-
receptor binding site from the immune system (Edwards et al., 2001).  The V3 loop is 
a very basic structure, and charge changes particularly at positions 302, 304, and 315 
are associated with viral tropism to either CCR5 or CXCR4 expressing cells.  Amino 
acid numbering of gp120 described here and across this document corresponds to the 
numbering detailed by the HXB2 liganded crystal structure (Kwong et al., 1998).   
Adhesion receptors 
In addition to binding receptors on T-cells that mediate infection, HIV-1 virions are 
also able to bind other cellular receptors.  Specific interactions with certain membrane 
proteins facilitate the rapid transport of infecting virions to various lymphoid tissues.  
A dense cluster of conserved oligomannose glycans on the outer domain of gp120 
may have a conserved functional role in creating a specific binding site for DC-SIGN 
receptors and other C-type lectins expressed on the surface of dendritic cells (Hong et 
al., 2007).  Through this interaction HIV virions are passively transported by dendritic 
cells from the mucosal tissue at the site of infection to secondary lymphoid organs 
rich in T-cells (Geijtenbeek et al., 2000).  Lectin interactions have also been 
implicated in facilitating the CD4 independent endocytic infection of astrocytes (Liu 
et al., 2004).  A tri-peptide loop in the V1-V2 domain comprised of residues 182-184 
mediates binding to α4β7 integrins on T-cells and natural killer cells, and facilitates 
transport to the gut-associated lymphoid tissue (Arthos et al., 2008).   
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Figure 3: The complex receptor binding sites of HIV-1 gp120 
A ribbon diagram of the HIV-1 envelope gp120 molecule depicting the CD4 binding site in purple and 
co-receptor binding site in cyan.  The remaining gp120ΔV1-V2 molecule is shown in grey.   
 
The role of Asn-linked glycans 
The envelope glycoproteins are extensively glycosylated by N-linked glycans (Figure 
4).  Since the same carbohydrate moieties are post-translationally attached to host cell 
glycoproteins, these glycans act as a non-immunogenic barrier that shields the 
underlying peptide structure from the immune system.  This divides the outer domain 
of gp120 further into a generally neutralisable and immunologically silent face based 
on epitope accessibility (Wyatt et al., 1998).  A particularly dense patch of glycans on 
the outer domain of gp120 is comprised of only high molecular weight mannose-rich 
glycans (Zhu et al., 2000).  They are resistant to mannosidases as a result of tight 
glycan packing, and are present in the context of both monomeric and native gp120 
(Doores et al., 2010).  The remaining glycans bordering the receptor binding sites and 
trimer interface are considerably more variable depending on the expression context.  
While some believe that the native envelope glycoproteins are covered in exclusively 
low molecular mass mannose-rich glycans, there is also convincing evidence to 
suggest that the viral trimer is dotted in an array of complex and hybrid glycans 
(Binley et al., 2010; Doores et al., 2010).  Viruses grown in N-
acetylglucosaminyltransferase I negative cells, which are unable to create hybrid or 
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complex glycans from mannosidase processed glycans, are ten-fold more sensitive to 
neutralisation by sCD4 (Binley et al., 2010).  This suggests that an important role 
does exist for the few complex/hybrid glycans associated with the native trimer in 
protection of conserved epitopes.  Glycans bordering the neutralisable face have been 
implicated in protecting the receptor binding sites and V3 loop from neutralising 
antibodies.  Specifically glycans at N197 (V1-V2 stem), N301 (V3 stem), and N386 
(V4 stem) have been implicated in protecting the CD4 and co-receptor binding sites 
(Gray et al., 2007b; Koch et al., 2003; Sanders et al., 2008b; Wu et al., 2009).  As 
with many glycoproteins the glycans on gp120 have been shown to be essential for 
proper folding of the molecule (Li et al., 1993).  Furthermore removal of the few 
glycosylation sites in gp41 prevents the gp160 protein from being properly processed 
and efficiently transported in the Golgi apparatus (Fenouillet and Jones, 1995).  Thus 
the extraordinary glycosylation of HIV-1 glycoproteins is highly conserved due to 
their multifaceted functional role.   
 
 
Figure 4: Extensive glycosylation of gp120 
A surface model of gp120 showing the CD4 binding site (yellow) and asparagine residues potentially 
linked to glycan (green).  The inner domain, outer domain, and bridging sheet are coloured brown, 
purple, and black respectively.  The molecule is rotated around 180° to show all potential glycosylation 
sites associated with an HIV-1 subtype C consensus gp120 monomer.   
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Neutralising antibodies 
Most HIV-1 infected individuals develop binding antibodies to immunodominant 
epitopes in gp41 within the first month of HIV-1 infection, followed to varying 
degrees by anti-gp120 antibodies (Tomaras et al., 2008).  These antibodies have no 
neutralising potential and often target the positively charged co-receptor binding site 
and V3 loop.  Autologous neutralising antibodies begin to develop within the first 
year of infection (Gray et al., 2007a; Tomaras et al., 2008).  By definition they are not 
cross-reactive and target epitopes defined by variable structures such as those 
contained in V1-V2, V4, and V5.  They develop to high titres, and exert enough 
immune pressure to force complete replacement of the viral population in vivo (Wei et 
al., 2003).  Autologous neutralising antibodies develop in sequential waves targeting 
multiple distinct epitopes throughout the course of natural infection. This continual 
selective pressure drives chronological waves of escape across the envelope 
glycoprotein (Moore et al., 2009).  However very few autologous antibody targets 
have been identified thus far, and their possible influence on the development of 
broadly cross-reactive neutralising antibodies later on in infection has yet to be 
elucidated.   
 
Recent data suggests that approximately 25% of all HIV-1 infected patients go on to 
develop a moderately broad neutralising antibody response much later after infection 
(Doria-Rose et al., 2009; Sather et al., 2009).  The lower frequency of these broadly 
cross-reactive antibodies in HIV-1 infected individuals when compared to the diverse 
autologous neutralising antibody response, as well as the later development of these 
antibodies, suggests that their highly conserved epitopes are less immunogenic than 
those recognised by strain-specific neutralising antibodies.  This presents a 
considerable obstacle for vaccine design aimed at inducing broadly cross-reactive 
neutralising antibodies.  An even smaller subset of the population (~1% of all HIV-1 
infected individuals) classified as elite neutralisers develop exceptionally potent and 
broadly cross-neutralising antibodies (Simek et al., 2009).  These antibodies probably 
best represent the kind of neutralising antibody response that must be induced by a 
vaccine immunogen.  By identifying monoclonal antibodies with epitopes in these 
conserved regions, researchers hope to better understand the requirements of a 
vaccine immunogen able to elicit such antibodies.   
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Broadly neutralising antibodies targeting the receptor binding sites 
The broadly cross-reactive neutralising antibody b12 recognises the CD4 binding site 
of gp120 and neutralises just under half of all primary isolates (Zhou et al., 2007).  
The crystal structure of Fabb12 bound to the gp120 core reveals that it makes contacts 
primarily with the structurally rigid components of the outer domain, and thus does 
not incur an unfavourable entropic penalty upon contact of its epitope (Kwong et al., 
2002; Zhou et al., 2007).  The b12 antibody has an 18 amino acid long CDRH3 with a 
tryptophan at its tip which buries into the hydrophobic pocket normally recognised by 
Phe
43
 of CD4 (Saphire et al., 2001).  Although this is longer than the average CDRH3 
length in human antibodies interacting with proteins, it is not uncommon for 
antibodies targeting viral pathogens or glycans structures (Collis, Brouwer, and 
Martin, 2003).  Crystal structures of gp120 bound to multiple CD4 binding site 
antibodies reveals that although they recognise only slightly divergent epitopes, the 
conformation of gp120 required for antibody interaction is not compatible with the 
predicted structure of the envelope trimer (Chen et al., 2009).  FabF105 binding to 
gp120 opens up the bridging sheet like a book, significantly displacing the V1-V2 
stem and exposing the hydrophobic face of the α1-helix in the inner domain.  Binding 
of the Fabb13 is similar to Fabb12 in that it recognises an epitope in the outer domain 
however the angle of binding is 17° divergent and this results in a 152° displacement 
of the V1-V2 stem.  In both cases the repositioning of the V1-V2 domain results in a 
predicted clash at the trimer interface and this is proposed to be the reason as to why 
these antibodies are non-neutralising.   
 
Recently several other CD4 binding site directed antibodies have been discovered 
(Wu et al., 2010).  Antibodies VRC01, VRC02, and VRC03 were all isolated from the 
same clade B infected individual (Wu et al., 2010).  VRC03 binds to the same epitope 
as b12 but has significantly broader cross-neutralising potential.  It has undergone 
extensive somatic mutation with 30% of its heavy chain residues and 20% of its light 
chain residues diverging from the germline sequence.  VRC01 and VRC02 are 
clonally related and recognise the complete CD4 binding site, with an almost identical 
enthalpy and entropy of binding when compared to CD4.  They are able to neutralise 
more than 90% of all viral isolates at remarkably low IgG concentrations and are the 
most broadly neutralising naturally occurring antibodies ever discovered.  
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Furthermore they have also undergone extensive affinity maturation of a magnitude 
comparable to VRC03.  HJ16 has a similar neutralisation breadth to b12, but 
recognises a distinct epitope that is not reliant on the Asp
368
 residue in the CD4 
binding loop important for most CD4 binding site antibodies described to date (Corti 
et al., 2010).  It almost exclusively neutralises primary isolates, and in particular 
neutralises those viruses that are insensitive to neutralisation by b12.  In fact a 
combination of antibodies HJ16 and b12 is able to neutralise more than two thirds of 
all HIV-1 isolates.  The HJ16 antibody binds a recently identified epitope adjacent to 
the b12 epitope and significantly dependent on residues Asp
474
, Met
475
, and Arg
476
 in 
the α5-helix that joins the inner and outer domains (Pietzsch et al., 2010).  The 
epitope has been designated CD4/DMR or more broadly gp120core, and is potentially 
present in a large fraction of all cross-reactive plasma (Scheid et al., 2009).   
 
The isolation of co-receptor binding site directed Fab fragments with high 
neutralisation potential initially hinted at the possibility of exploiting this region in 
vaccine design (Moulard et al., 2002).  Often these CD4 induced antibodies have long 
CDRH3 loops that are sulphated in an effort to mimic the sulphated N-terminus of 
chemokine receptors (Choe et al., 2003).  However in the context of IgG these 
molecules lose their neutralisation potency due to the steric constraints imposed by 
the host membrane following CD4 engagement (Labrijn et al., 2003).   
Broadly neutralising antibodies targeting gp41 
Three anti-gp41 broadly neutralising antibodies (2F5, 4E10, and Z13) have been 
identified that target an overlapping epitope in the membrane proximal ectodomain 
region (MPER) of gp41 (Zwick et al., 2001).  In addition to binding between host and 
viral membranes and thus sterically obstructing the fusion process, these antibodies 
also act to immobilise a hinge mechanism in the MPER which normally bends the 
viral membrane towards the host membrane after receptor engagement (Song et al., 
2009).  Two of these antibodies (2F5 and 4E10) again have unusually long CDRH3 
regions with hydrophobic residues at their apex which are not involved in peptide 
binding but rather are essential for neutralisation by interacting with the viral 
membrane (Alam et al., 2009; Julien et al., 2010).  Such auto-reactive antibodies are 
usually down-regulated in the context of a healthy immune system (Haynes et al., 
2005).   
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Broadly neutralising antibodies dependent on glycans 
The broadly neutralising antibody 2G12 recognises a mannose rich glycan 
arrangement on the immunologically silent face of gp120 (Sanders et al., 2002; 
Scanlan et al., 2002).  This antibody has an unusual proline at residue 113 in the 
heavy chain framework at the base of the Fab domain.  This facilitates an exchange of 
heavy chain variable domains allowing them to pair with the opposite arm light chain 
variable domains in the context of a single immunoglobulin (Calarese et al., 2003).  
Thus 2G12 creates a third antigen combining site at the variable domains heavy chain 
juncture, and this increases the binding avidity and thus allows for efficient 
recognition of carbohydrate.  More recently, by mapping the targets of plasma from 
individuals with broadly neutralising antibodies, a novel target dependent on the 
glycan at Asn
332
 (also important for 2G12) has been identified (Walker et al., 2010).   
 
While antibodies to the V3 domain are for the most part non-neutralising due to steric 
occlusion, two antibodies named PG9 and PG16 (which are somatic variants of each 
other) have been identified that bind to a novel epitope in the V2-V3 domains of HIV-
1 (Walker et al., 2009).  These antibodies neutralise roughly 80% of all viral isolates 
and are very potent.  This discovery was novel in that the V1-V2 domain was 
previously thought to only elicit type-specific neutralising antibodies (Kimura et al., 
2009).  PG9 and PG16 have the longest CDRH3 loops of all the above discussed 
monoclonal antibodies, with twenty eight amino acids forming a unique tyrosine 
sulphated sub-domain (Pejchal et al., 2010).  Again, about fifteen to twenty percent of 
the heavy and light chain variable regions have been affinity matured (Pancera et al., 
2010b).  Although both antibodies display much sequence similarity, they recognise 
distinct but overlapping epitopes.  PG16 is more heavily reliant on amino acids in V3 
(Walker et al., 2009).  While both antibodies are reliant on the glycan at Asn
160
 for 
proper epitope formation, PG16 is more sensitive to the precise glycosylation pattern 
of the envelope trimer (Doores and Burton, 2010).  Collectively this data suggests that 
broadly neutralising antibodies appearing later in infection probably result from the 
affinity maturation of either autologous neutralising antibodies or other non-
neutralising antibodies.  This provides a new argument for identifying novel targets 
for autologous neutralising antibodies, and understanding the role they play in the 
development of broadly cross-reactive neutralising antibodies.   
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A novel target for autologous neutralisation in the outer domain 
Along with the V1-V2 loops the solvent exposed outer domain is the primary target 
for neutralising antibodies.  Recent work from our laboratory identified a novel target 
for autologous neutralising antibodies in the outer domain comprised of amino acids 
in the V4 loop and adjacent C3 region (Moore et al., 2008).  The outer domain 
represents a conformationally stable β-barrel structure stabilised by inter-sheet 
hydrogen bonding as well as disulphide bonds at the base of V4, V3, and connecting 
C3 to C4 (Sanders et al., 2008a; Zhou et al., 2007).  Most proximal to the bridging 
sheet the β-barrel structure is narrower and bulges out only to form the CD4 binding 
loop.  At the opposite end of the β-barrel the amphipathic α2-helix is nestled between 
loop structures in C2, V4, and V5.  These two alpha helices (the α2 and α3 helices) 
associated with the outer domain are contained exclusively within the C3 region of 
gp120 (Figure 5).  Between the α2- and α3-helices in the C3 region is a highly 
variable β-sheet (β14).  This sheet interacts with β-sheets in V4(β18) and V5(β24), 
and serves to bind these three structures together.   
 
 
Figure 5: The outer domain forms a β-barrel that wraps around the α2-helix 
The outer domain is coloured according to secondary structure with α-helices, β-sheets, and connecting 
loop structures coloured red, yellow, and green respectively.  The C3 region contains the conserved 
CD4 binding loop, as well as the more variable α2-helix flanked by V4 and V5.  Variable anti-parallel 
β-sheet structures β14(C3), β18(V4), and β24(V5) interact closely with each other.   
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Subtype specific selective pressures 
Different regions of the HIV-1 envelope are subject to varying selective pressures in 
different clades (Choisy et al., 2004).  In particular the V3 loop is more conserved in 
subtype C viruses when compared to subtype B viruses, while the α2-helix of subtype 
C is under greater selective immune pressure (Gaschen et al., 2002).  The α2-helix has 
a more conserved amphipathic structure in subtype C when compared to other clades, 
with amino acids at positions 336 and 346 (Figure 6) more likely to be hydrophilic in 
subtype C, suggesting greater exposure of the helix (Gnanakaran et al., 2007).  By 
superimposing the crystal structure of a recently published subtype C gp120 with the 
previously determined subtype B gp120 structures, and a recently crystallised subtype 
A gp120, the α2-helix of the clade C glycoprotein can be seen to be relatively more 
solvent exposed (Figure 7).  In addition the V4 loop is generally shorter in subtype C 
when compared with subtype B and overall the α2-helix also shows a strong 
correlation of charge compensation with V4, where the α2-helix is more positively 
charged and the V4 more negative (Gnanakaran et al., 2007).   
 
 
 
 
Figure 6: The subtype C α2-helix is more amphipathic 
Helical wheel plot diagrams of the α2-helix from consensus subtype B gp120 and consensus subtype C 
gp120 sequences.  The α2-helices are shown winding into the page from C-terminus (position 352) to 
N- terminus (position 335).  Hydrophobic, non-charged polar, positively charged, and negatively 
charged amino acids are coloured brown, green, blue, and red respectively.  The N-linked glycosylation 
site associated with the α2-helix is indicated with the  symbol and underlined in the sequence.   
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Figure 7: The subtype C α2-helix is more solvent exposed on monomeric gp120 
The crystal structures of the HIV-1 gp120 C3 region from subtype B isolates HIV-1HXB2 (purple), HIV-
1YU2 (blue), and HIV-1JR-FL (green), as well as the subtype A isolate HIV-193TH057 (red) were  all 
superimposed on the subtype C structure of HIV-1CAP210 (yellow) using the Swiss-PdbViewer 
programme (Guex and Peitsch, 1997).  Structures were obtained from the pdb files 1G9M, 2QAD, 
2B4C, 3NGB, and 3LQA.   
 
 
Acquisition of length in the V4 loop is associated with resistance to autologous 
neutralising antibodies, and it could be speculated that part of this role involves 
escape via epitope occlusion from antibodies targeting the α2-helix.  However, 
transfer of the α2-helix alone from a neutralisation sensitive donor virus to a 
neutralisation resistant recipient virus often does not alter the neutralisation phenotype 
of the latter (Rong et al., 2007).  In contrast, by transferring the entire C3-V4 region it 
was possible to completely transfer neutralisation sensitivity to early autologous 
plasma, suggesting that the entire region was required to reconstitute these types of 
neutralisation epitopes (Moore et al., 2008).  In this original study four individuals 
from the CAPRISA_002 Acute Infection Cohort (described below) were identified as 
containing anti-C3-V4 autologous neutralising antibodies: CAP45, CAP63, CAP84, 
and CAP88 (Appendix A).  They were identified by creating heterologous chimeric 
viruses for the C3-V4 region as described above.  The neutralisation epitopes 
recognised by CAP88 antibodies appeared to be directed towards the C3 region alone.  
Transferring the HIV-1CAP88 C3 region into a resistant heterologous virus resulted in 
the complete transfer of neutralisation sensitivity, while transferring the V4 region 
alone did not confer any neutralisation sensitivity.  Similarly by transplanting the 
HIV-1CAP63 V4 region only, but not the C3 region alone, partial sensitivity to CAP63 
plasma was transferred.  This suggested that the epitopes recognised by CAP63 
antibodies were more dependent on residues in V4 than in C3.  In addition the use of 
viruses chimeric for other regions also allowed for the identification of other epitopes 
CAP210-E8 
HXB2 
CAP210-E8 
YU2 
CAP210-E8 
JR-FL 
CAP210-E8 
93TH057 
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for autologous neutralising antibodies in V1-V2 for participants CAP45 and CAP88, 
and in V5 for participant CAP84.  Each chimera was tested for the acquisition of an 
unnaturally sensitive neutralisation phenotype by testing them against heterologous 
serum samples from multiple HIV-1 infected individuals.  Since almost all HIV-1 
infected individuals develop anti-V3 and anti-CD4 binding site antibodies, if the 
chimeric viruses adopted an exposed conformation they should become sensitive to 
heterologous plasma samples.  None of the chimeras became universally sensitive to 
these unrelated plasma samples, suggesting that their neutralisation was mediated by 
strain-specific antibodies (Moore et al., 2008).   
Escape from autologous neutralising antibodies 
A second study from our lab looked at escape from autologous neutralising 
antibodies, and included participants CAP45 and CAP88 (Moore et al., 2009).  The 
authors showed that the virus infecting CAP88 isolated at one month post infection 
was sensitive to the anti-C3 antibodies in CAP88 plasma, while the virus isolated 
from six months post infection was not.  Sequence analysis identified three amino 
acids in the α2-helix under selective pressure.  The acquisition of a potential N-linked 
glycosylation site at position (339 normally found in most viruses) and a charge 
change from glutamic acid to lysine at either position 343 or position 350.  The 
potential glycosylation site acquired at position 339 was highly conserved by six 
months post infection, while the charge changes at positions 350 and 343 were each 
present  in 50% of the population, suggested that their roles in escape were mutually 
exclusive.  Amino acids at positions 343 and 350 have been previously identified as 
being under considerable selection pressure in subtype C viruses (Rong et al., 2007).  
They map to the same face of the helix as position 339, and are in a position to 
interact directly with V4 (Figure 8A).  Removing the glycan at position 339 in a six 
month clone resulted in the partial restoration of neutralisation to plasma from an 
earlier time frame (Figure 8B, purple line).  Once the charge change at position 350 
was also incorporated, the six month virus became completely sensitive to earlier 
plasma (Figure 8B, pink line).   
 
Escape mutations to neutralising antibodies in CAP45 plasma were also identified in a 
similar way.  CAP45 had been previously shown to develop an antibody response to 
V1-V2 and C3-V4 (Moore et al., 2008).  Of those residues identified as being under 
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positive selection, one amino acid in V1 (N147S) and two in V2 (R186K/E190aG
1
) 
were back mutated in a clone isolated at 12 months post infection.  In so doing the 
later virus became partially sensitive to neutralisation by earlier serum samples 
(Moore et al., 2009).  This was consistent with the previously identified anti-V1-V2 
activity in CAP45 plasma.  Surprisingly back-mutation of two residues in V5 (E460K, 
and G462D) made the later virus almost completely sensitive to plasma from all 
earlier time points.  It was hypothesised that these two mutations must confer escape 
to the anti-C3-V4 antibodies, since back-mutation of all the remaining positively 
selected mutations in the escaped virus could not restore any sensitivity to earlier 
plasma samples (Figure 8B).   
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Figure 8: Escape mutations to CAP88 antibodies map to the α2-helix 
(A) Helical wheel plot diagrams showing the CAP88 α2-helix winding into the page from C-terminus 
to N-terminus.  The wild-type helix is shown on the left, while the escaped helix is shown on the right.  
Amino acids under positive selection at six months post infection are indicated with the orange arrows.  
The location of the V4 loop is shown in purple, and the adjacent N-linked glycosylation site is 
indicated.   Amino acids are coloured as in Figure 6.  (B) Escape from CAP88 neutralising antibodies 
(adapted from Moore et al., 2009).  Titres against the one month infecting clone (yellow), six month 
clone (red), N339I back-mutant (purple), and N339I/E350K double mutant (pink) are shown.   
 
                                                 
1
 Referred to as R181K/E186G in the Moore et al., 2009 study based on HIV-1CAP45 numbering 
A 
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Project Aim 
There is very little research published to date on autologous neutralising antibodies, 
with most of the work focused on identifying and characterising broadly cross-
reactive antibodies.  Autologous neutralising antibodies report which regions of the 
native envelope trimer are exposed for antibody mediated neutralisation.  
Furthermore they may provide important clues as to the origins of broadly 
neutralising antibodies.  Given the recent identification of the C3-V4 region as a 
complex neutralisation epitope within gp120, the aim of this project was to better 
define the nature of this epitope in hope that it will contribute to the knowledge 
necessary to develop an HIV vaccine.   
Main Objective 
To determine whether C3-V4 autologous neutralising antibody epitopes are contained 
wholly within monomeric gp120, and to further characterise the nature of escape 
from the antibodies targeting this site.   
Specific Objectives 
 To determine whether the autologous neutralising antibodies in serum samples 
from CAPRISA_002 participants CAP45, CAP84, CAP63, and CAP88 could 
be adsorbed using autologous monomeric gp120.   
 To ascertain whether these same serum neutralising antibodies could be 
adsorbed using chimeric gp120 containing an autologous C3-V4 region 
grafted into a heterologous gp120 backbone.   
 To assess the effect of escape mutations introduced into wild-type autologous 
monomeric gp120 on the adsorption of anti-C3-V4 directed neutralising 
antibodies.   
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Chapter Two: Materials and Methods 
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The CAPRISA_002 Acute Infection Cohort 
The cohort, enlisting 245 women at high risk for HIV infection, has been described 
previously (Gray et al., 2007a; van Loggerenberg et al., 2008).  Sixty two women 
became infected with HIV and were enrolled into the study.  They have been 
extensively monitored including CD4 count, viral load, and regular plasma/serum 
sampling.  Although the primary aim was to document the evolution of the virus and 
host immune response during the course of acute infection, the majority of the 
participants have been successfully enrolled for more than three years and some as 
long as five.   
The PPI4 expression vector 
The pPPI4 expression vector was developed by Progenics Pharmaceuticals Inc. (New 
York, U.S.A.), and contains several elements designed to enhance recombinant gp120 
expression as described previously (Binley et al., 2000; Trkola et al., 1996).  These 
include a cytomegalovirus major immediate-early promoter-enhancer for high level 
constitutive expression, a tissue plasminogen activator signal peptide for efficient 
secretion of soluble gp120, and a bovine growth hormone polyadenylation signal to 
stabilise the transcribed mRNA.   
Creating histidine tagged gp120 expressing plasmids 
The gp120 coding regions of four subtype C viruses were amplified from plasmids 
containing the full length envelope genes.  The envelope clones and their GenBank 
accession numbers are: CAP45.2.00.G3J (EF203960), CAP63.2.00.A9J (EF203973), 
CAP84.2.00.32J (EF203963), and CAP88.2.00.B5J (EF203927).  Each of the four 
viruses represents the relatively homogenous infecting population circulating in four 
individuals of the CAPRISA cohort approximately one month post-infection, prior to 
the development of neutralising antibodies.  They are thus sensitive to all host 
autologous neutralising antibodies.  For each of these distinct envelope clones, a set 
of chimeric pseudoviruses was previously engineered (Moore et al., 2008).  For 
instance, the C3-V4 region of HIV-1CAP88 (sensitive to CAP88 plasma) was grafted 
into the HIV-1CAP63 (resistant to CAP88 plasma) envelope backbone to produce the 
heterologous chimera HIV-1CAP63-88(C3-V4)-63.  This chimeric virus was then tested for 
any acquired sensitivity to CAP88 plasma, which confirmed the role of the C3-V4 
region as a target for CAP88 neutralising antibodies.  Additional chimeric 
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pseudoviruses were also created in this study (described below).  From some of these 
new chimeric envelope encoding plasmids, the previously engineered C3-V4 
chimeric plasmids, and the parental sequences, the gp120 coding regions were 
amplified.  In addition several mutations were also introduced into the gp120 
constructs (described below).  A summary of the parental, chimeric, and mutant 
template sequences used for gp120 production has been provided in Figure 9.  A 
summary of the chimeric pseudoviruses created for this study is shown in Figure 10.   
 
 
Figure 9: Template sequences used for gp120 production 
A schematic summary of the different template sequences used for gp120 production in this study.  
The gp120 coding sequence corresponding to HIV-1CAP45, HIV-1CAP63, HIV-1CAP84 and HIV-1CAP88 is 
coloured pink, yellow, green, and brown respectively.  The red dots indicate those gp120 constructs 
into which the D368R mutation was introduced, while the blue dots indicate the gp120 constructs into 
which previously identified escape mutations were introduced.   
 
 
Primers KpnIEnvC and BstBI-HT-re were used to amplify all gp120 coding regions.  
Sequences for these as well as all subsequent primers used in this study are listed 
below (Table 1).  The PCR protocols included thirty five cycles, with an annealing 
temperature of 50 °C for thirty seconds.  Denaturation and extension times and 
temperatures varied according to the manufacturer’s recommendations for each of the 
different high fidelity enzymes used.  Although primer melting temperatures and 
actual annealing temperatures used varied by as much as 10 degrees, no non-specific 
binding was expected given the nature of the plasmid DNA template.  A codon 
optimised plasmid encoding the CAP63 gp120 and chimeric CAP63-88(C3)-63 
gp120 was obtained from Dr. Liao (Duke Human Vaccine Institute, North Carolina, 
U.S.A.) to facilitate a greater level of gp120 production.  In order to PCR amplify 
these gp120 encoding genes for downstream sub-cloning, the primers 
CAP63(Codop)-KpnI-fo and CAP63(Codop)-Histag-BstBI-re were designed using 
the online OligoCalc tool (Kibbe, 2007).  These were used in the same manner as the 
KpnIEnvC and BstBI-HT primer pair described above.   
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All PCR products were treated with 10 U - 20 U DpnI at 37 °C for one to two hours 
to digest the methylated template DNA, and then purified with the Qiagen PCR 
purification kit (Hilden, Germany) using the protocol provided.  The KpnIEnv and 
CAP63(Codop)-KpnI-fo primers introduced a KpnI cut site into the N-terminus of 
gp120, while the BstBI-HT-re and CAP63(Codop)-Histag-BstBI-re introduced a 
BstBI cut site, six histidine residues (HisTag) preceded by a flexible Gly-Gly-Ser 
linker motif, and two stop codons into the C-terminus of gp120.  This allowed for the 
directional cloning of PCR products in to the mammalian expression vector pPPI4.  
PCR products were digested with 50 U KpnI for one hour at 37 °C, and then 20 U 
BstBI for one hour at 65 °C in the appropriate buffers supplied.  Following each 
digestion the PCR product was again purified using the Qiagen kit.  Approximately 2 
μg of the destined expression vector pPPI4 (harbouring an irrelevant gp120 gene) was 
digested simultaneously.  The linearisation of the vector, and liberation of its 
associated gp120 open reading frame was monitored on a 1% agarose gel in Tris-
Acetate buffer (supplemented with 0.5 μg/mL ethidium bromide), and the digestion 
times were manipulated accordingly.   
 
The enzymatically digested vector and PCR products were gel purified using the 
Qiagen gel extraction kit and protocol provided.  All DNA concentrations in this 
study were determined using a NanoDrop
TM
-1000 Spectrophotometer (Thermo 
Scientific, Wilmington, U.S.A.).  A ratio of 3:1 PCR product to linearised vector was 
then incubated overnight at 16°C in the presence of Invitrogen T4-phage DNA ligase 
(Carlsbad, U.S.A.) in the buffer supplied.  Ligation products were used to transform 
Escherichia coli XL10-Gold chemically competent cells produced by Stratagene (La 
Jolla, USA) in the presence of β-mercaptoethanol according to the 42 °C heat shock 
method provided.  Cells were recovered in a nutrient-rich super optimal broth with 
catabolite suppression (SOC) medium for one hour at 37 °C with shaking (225 Hz) 
and plated onto Luria Bertani (LB) media supplemented with 100 μg/mL ampicillin at 
37 °C overnight to selectively isolate single colonies.  These were subsequently 
cultured in 50 μL Luria Bertani broth supplemented with 300 μg/mL ampicillin for 
one hour, and then screened for positive transformants by PCR using the 
KpnIEnv/BstBI-HTre or CAP63(Codop)-KpnI-fo/CAP63(Codop)-Histag-BstBI-re 
primer pairs.  Successful transformants were selected for plasmid extraction and 
confirmation of the inserted gene by DNA sequencing.   
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Table 1: List of primers used in this study 
PCR primers 
KpnIEnvC GTCTATTATGGGGTACCTGTGTGGAAAGAAGC 
BstBI-HT-re CCCACTAAATCAAAAAGGAGAGTGGTGGAGTCAGAAAAAGGCGGATCCCACCACCACCACCACCACTGATGATTCGAAGCGAGG 
CAP63(Codop)-KpnI-fo ACGGGGTACCCGTGTGGCGCGAGGCCAAGACCACC 
CAP63(Codop)-Histag-BstBI-re CAGATTCGAATCATCAGTGGTGGTGGTGGTGGTGGGATCCGCCGCGCTTCTCGCGGCCCACC 
V1-fwd GTGTAAAGTTGACCCCACTCTG 
V1-rev CAGAGTGGGGTCAACTTTACAC 
V2-fwd CAGGCCTGTGTTATGGTTGAGG 
V2-rev CCTCAACCATAACACAGGCCTG 
84-45V5fo GATGGAGGGAAAACAGACAGGAATGACACAGAGATATTCAGACCTGCAGGAGG 
84-45V5re GACATTCCTGTCTGTTTTCCCTCCATCACGTGTCAGCAGTAGTCCCGTGATAC 
84-45β14flankfo TTCCTTAATAGAACAATAGAATTTGAACCACCCTCAGGAGGGGATCTAG 
84-45β14flankre GGGTGGTTCAAATTCTATTGTTCTATTAAGGAAGTGTTCCTTTAATTTTTCCTT 
T7 TAATACGACTCACTATAGGG 
EnvAdir CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA 
EnvM TAGCCCTTCCAGTCCCCCCTTTTCTTTTA 
Sequencing primers 
T7 TAATACGACTCACTATAGGG 
tPA-fo CCATGCCCGATTCAGAAGAGGCGCCAG 
EnvAdir CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA 
KpnIEnvC GTCTATTATGGGGTACCTGTGTGGAAAGAAGC 
E175 TTTAGCATGTGATGCACAAAATAG 
EnvB AGAAAGAGCAGAAGACAGTGGCAATGA 
A589 GTGTAAAGTTAACCCCACTCTG 
A590 AATCGCGAAACCAGCCGGCGCACAAT 
Br AATTTCTAGGTCCCCTCCTGA 
Df AGCACATTGTAACATTAGT 
E55 GCCCCAGACTGTGAGTTGCAACAGATG 
E85 GTCCCTCATATCTGCTCCTCCAGGTCTG 
EnvArev TGCTGCTCCCAAGAACCCAA 
gp41Fo GCCAGTGGTATCAACTCAAC 
BstBI-HT-re CCCACTAAATCAAAAAGGAGAGTGGTGGAGTCAGAAAAAGGCGGATCCCACCACCACCACCACCACTGATGATTCGAAGCGAGG 
Nr GGTGAGTATCCCTGCCTAACTCTA 
E210 TAACAAATTGGCTGTGGTATATAA 
E240 ATAATGATAGTAGGAGGCTTGATAGGC 
MPERseq CACAAGCACAATATACAGGTTACTTGAAGACTCGCAAAACCAGCAGG  
EnvM TAGCCCTTCCAGTCCCCCCTTTTCTTTTA 
PPI4-re GGCAAACAACAGATGGCTGGCAACTAGAAG 
63Codop-PLCV-re GCAGTTCAGGGTCACGCACAGG 
63Codop-C1HED-fo CAGATGCACGAGGACATCATCTCC 
63Codop-PVVSTQ-fo GTGGTGTCCACCCAGCTGCTG 
63Codop-NNAKT-re CGATGATGGTCTTGGCGTTGTTGG 
63Codop-FFYC-fo CGAGTTCTTCTACTGCAACACCTCC 
63Codop-PCRIKQ-re CTGCCACATGTTGATGATCTGCTTGATG 
Mutagenesis Primers 
CAP45-(K460E/D462G)-fo CACGTGATGGAGGGGAAACAGGCAGGAATGACACAGAG 
CAP45-(K460E/D462G)-re CTCTGTGTCATTCCTGCCTGTTTCCCCTCCATCACGTG 
CAP88-I339N-E443K-fo ACTAAAGACAGATGGAACGCAACTTTAAAAAAGGTAAAGAAGAAA 
CAP88-I339N-E443K-re TTTCTTCTTTACCTTTTTTAAAGTTGCGTTCCATCTGTCTTTAGT 
CAP45D368Rfo CACCCTCAGGGGGGCGTCTAGAAGTTACAACAC 
CAP45D368Rre GTGTTGTAACTTCTAGACGCCCCCCTGAGGGTG 
CAP84.32-D368Rfo CCAGTCTCAGGAGGGCGTCTAGAAGTTACAACACATAGC 
CAP84.32-D368Rre GCTATGTGTTGTAACTTCTAGACGCCCTCCTGAGACTGG 
*Primers designed specifically for this study are shaded grey   
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Creating chimeric pseudovirions 
Plasmids encoding wild-type and C3-V4 chimeric envelope constructs for 
pseudovirion production have been engineered previously (Moore et al., 2008).  
However this project required the generation of several additional chimeras.  Primers 
84-45V5fo, 84-45V5re, were used in conjunction with EnvAdir and EnvM to create 
the chimeric HIV-1CAP84-45(C3+V5)-84 pseudovirus construct from the HIV-1CAP84-45(C3)-84 
encoding plasmid.  Primers 84-45β14flankfo and 84-45β14flankre (again with 
EnvAdir, EnvM, and plasmid HIV-1CAP84-45(V5)-84) were used to create the HIV-1CAP84-
45(β14+V5)-84 chimera.  Primers A589 and A590 were used with the EnvAdir/EnvM 
combination to introduce the HIV-1CAP45 V1-V2 loop into the HIV-1CAP84-45(C3-V4)-84 
chimera.  Both early and escaped V1-V2 sequences were introduced this way.  A 
schematic describing the construction of these chimeras is shown in Figure 10.  The 
HIV-1CAP84-45(C3+V5)-84 pseudovirus was selected for gp120 production (as described 
above).  The primer pair EnvAdir/EnvM was used to amplify full length envelope 
genes which were then cloned into the pcDNA 3.1D-TOPO expression vector from 
Invitrogen using the protocol provided.  Ligation products were used to transform 
ultra-competent cells as described above and positive transformants were selected by 
PCR using a primer specific for the vector (T7) as well as EnvM.  Chimeric 
envelopes were then confirmed by DNA sequencing (described below).   
 
Pseudoviruses were produced in mammalian 293T cells grown in DMEM 
supplemented with 10% FBS, 50 μg/mL gentamycin, and 25 mM HEPES buffer.  
This was done by co-transfecting envelope genes with the pSG3ΔEnv HIV-1 subtype 
B backbone plasmid.  Transfections were executed with FuGENE
®
6 (described 
above) using 80 ng/cm
2
 of each plasmid and a 3:1 ratio of FuGENE
®
6 to plasmid 
DNA.  After 48 hours the cell culture supernatant was filtered through 0.45 μm and 
adjusted to 20% FBS, before being stored at -70 °C for later use in the neutralisation 
assays.  The pseudovirion particles that are produced express functional gp160 
trimers on their envelope surfaces, but do not encode a functional envelope gene and 
are thus only capable of a single round of infection.  Pseudoviruses at various 
dilutions were co-incubated in a 96-well flat bottom plate with 10 000 TZM-bl 
reporter cells per well to a total volume of 250 μL for 48 hours at 37 °C.  TZM-bl 
cells are engineered to constitutively express CD4, CCR5, & CXCR4, and encode a 
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luciferase gene under the transcriptional control of the long terminal repeat element of 
HIV-1.  After 48 hours 150 μL was removed from each well and the cells were lysed 
with 100 μL of a luciferin containing Bright-Glo™ Luciferase Assay Buffer 
(Promega, Fitchburg U.S.A.) for two minutes.  Finally 150 μL of lysate was 
transferred to black F96 MicroWell Plates manufactured by NunC (Roskilde, 
Denmark), and the relative light units (RLU) produced measured in a VICTOR
3™ 
Multilabel Counter 1420 (PerkinElmer, Waltham, U.S.A.).   
 
 
Figure 10: New chimeras created for this study 
A schematic diagram describing how various chimeric pseudoviruses were engineered for this study.  
As in Figure 9 the gp120 coding sequence corresponding to HIV-1CAP45 was coloured pink, while the 
HIV-1CAP84 coding sequence was coloured green.  Structures are included to illustrate how genetically 
distant regions of the envelope may come together in the context of a gp120 monomer to provide a 
single, discontinuous neutralisation epitope.  The location of the flexible V1-V2 loop in the CD4 
bound conformation of gp120 is not known, and approximated with the coloured bubbles.   
 
Mutagenesis 
Amino acid changes used to map antibody specificities and evaluate the effects of 
known escape mutations were introduced with the QuikChange™ site-directed 
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mutagenesis kit from Stratagene (La Jolla, USA).  Primers for this purpose were 
designed based on the manufacturer’s recommendations.  The primer pairs CAP45-
(K460E/D462G)-fo / CAP45-(K460E/D462G)-re and CAP88-I339N-E443K-fo / 
CAP88-I339N-E443K-re were used to introduce known escape mutations into the V5 
loop and α2-helix of HIV-1CAP45 gp120 and HIV-1CAP88 gp120 respectively.  The 
primer pairs CAP45D368Rfo / CAP45D368Rre and CAP84.32-D368Rfo / 
CAP84.32-D368Rre were designed to introduce the D368R mutation into the CD4 
binding loop of HIV-1CAP45 gp120, HIV-1CAP45-84(C3V4)-45 gp120, and HIV-1CAP84 
gp120.  Mutagenesis reaction products were digested with DpnI at 37 °C for two 
hours to remove the methylated template sequence, and then used to transform 
chemically competent cells as described above.  Up to eight colonies were selected 
from each plate for plasmid extraction and DNA sequencing.   
DNA sequencing 
Plasmids were extracted from LB broth cultures using either the Qiagen Miniprep kit 
or the Sigma Midiprep kit (St.Louis, U.S.A.) depending on the amount of plasmid 
required for downstream experiments.  Extractions were done according to the 
protocol provided with the exception that triple the volume of culture advised was 
used for each extraction to increase yields.  Plasmids were sequenced using the 
BigDye™ Terminator v3.1 Cycle Sequencing Kit from Applied Biosystems (Foster 
City, U.S.A) and the Half-Dye Mix from Bioline (London, U.K.) in a 20 μL reaction 
using an in-house optimised reaction mix.  Primers T7, tPA-fo, EnvAdir, KpnIEnvC, 
E175, EnvB, A589, A590, Br, Df, E55, E85, EnvArev, gp41Fo, BstBI-HT-re, Nr, 
E210, E240, EnvM, PPI4-re, and MPERseq were used in varying combinations to 
sequence either gp120 or full length Env.  Primers 63Codop-PLCV-re, 63Codop-
C1HED-fo, 63Codop-PVVSTQ-fo, 63Codop-NNAKT-re, 63Codop-FFYC-fo, and 
63Codop-PCRIKQ-re were designed using OligoCalc to sequence the sub-cloned 
codon optimised plasmids.  Sequencing reaction products were precipitated out with 
120 mM sodium acetate in 100% ethanol at 2000 x g for thirty minutes.  The pellet 
was rinsed with 70% ethanol at 2000 x g for five minutes, and then dried for three 
minutes at 63 °C and resuspended in 10 μL Hi-Di™ Formamide from Applied 
Biosystems.  The sequences were resolved on an Applied Biosystems 3100 automated 
genetic analyser, and analysed using Sequencher v4.5 from Genecodes (Ann Arbor, 
U.S.A.).   
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Expression of recombinant gp120 
A polyethyleneimine (PEI) expression protocol was used for the transfection of 293T 
cells.  A similar protocol has been described previously (Kirschner et al., 2006).  
Polyethyleneimine with an average molecular weight of 25 kDa from Polysciences 
(Warrington, U.S.A.) was prepared to a 1 mg/mL solution in sterile water and filtered 
through 0.22 μm.  The 293T cells were seeded at 40 000 cells/cm2 24 hours prior to 
transfection to achieve approximately 80% confluency.  To optimise the transfection 
protocol different ratios of PEI:DNA (160 ng/cm
2
 plasmid DNA) were used to 
transfect a codon optimised gp120 encoding gene derived from HIV-1Du151.  The 
plasmid DNA was pre-incubated with PEI in Invitrogen serum-free DMEM at 1/20
th
 
of the final cell culture volume for 45 minutes.  Cells were transferred to serum-free 
DMEM and the transfection reaction mixture was added.  After five to six hours the 
medium was changed to DMEM supplemented with 10% FBS, and 50 µg/mL 
gentamycin.  The level of gp120 expression using PEI was compared with the 
commercial transfection reagent FuGENE
®
6 from Roche Applied Science 
(Mannheim, Germany).  These reactions were also set up according to the 
manufacturer’s guidelines with varying ratios of DNA:FuGENE®6 (using 160 ng/cm2 
plasmid DNA) in DMEM supplemented with 10% FBS, and 50 µg/mL gentamycin.   
 
From each transfection procedure cell culture media containing expressed soluble 
gp120 was collected after 48 hours and added to 96-well ELISA plates pre-coated 
overnight at 4 °C in a carbonate-bicarbonate buffer (pH 8.5) with D7324, a sheep 
anti-gp120 antibody produced by Aalto (Dublin, Ireland).  After one hour incubation 
at 37 °C the bound HIV-1 envelope proteins were detected using the ELISA protocol 
described below.  Once an optimal transfection protocol was identified it was scaled 
up to 500 mL culture volumes to increase expression levels for subsequent adsorption 
experiments, and the gp120 containing cell culture media was collected at three to 
four subsequent 48 hour intervals.  Cellular debris was pelleted at 4210 x g for 20 
minutes, and the supernatant was stored at -70 °C for later purification.   
Purification of recombinant gp120 
Cell culture supernatants containing the same recombinant gp120 proteins were 
pooled together in 2 L batches and filtered though 0.22 μm.  The filtrate was then 
passed through a Galanthus nivalis derived lectin affinity chromatography matrix 
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(from Sigma) three times to ensure retention of the major glycosylated fraction.  The 
protein bound beads were washed with roughly twenty column volumes of PBS 
containing 0.5 M sodium chloride to displace any non-specifically bound proteins, 
and then soaked in 50 mL of 1 M methyl-α-D-mannopyranoside in PBS for one hour 
to elute the bound glycoproteins.  The elution was concentrated in PBS to less than 2 
mL and then passed through a Q-sepharose anion exchange matrix (GE Healthcare, 
Little Chalfont, U.K.) at 0.3 μL/min in PBS.  This process was automated on the 
Amersham AKTAprime™ (now GE Healthcare, Little Chalfont, U.K).  Unwanted 
proteins were bound to the matrix and the column flow through containing histidine 
tagged recombinant gp120 was collected and concentrated to 5 mg/mL using the 
Vivaspin 20 centrifugal concentrators from Sartorius Stedim (Aubagne, France).  
Aliquots were supplemented with the cOmplete™ protease inhibitor cocktail from 
Roche (Penzburg, Germany) and stored at -20 °C.  Due to the relatively variable 
expression levels of gp120 derived from different viral strains, the same recombinant 
proteins were expressed on numerous occasions and different batches were each 
assessed qualitatively by SDS-PAGE and ELISA (described below).  All protein 
concentrations were determined using a NanoDrop
TM
-1000 Spectrophotometer 
(Thermo Scientific).   
Qualitative assessment of recombinant gp120 
Protein purity was assessed via SDS-PAGE.  20 μg of purified sample was run on an 
8% polyacrylamide gel and then stained overnight with Coomasie blue.  The relative 
proportion of gp120 to other protein species in the sample was calculated on the Bio-
Rad Molecular Imaging® Chemi Doc XRS™ using the Quantity One software 
(Hercules, U.S.A.).  Purity of 85% gp120 and above was tolerated for downstream 
applications.  Since the introduction of heterologous protein sequence into the 
chimeric gp120 may deform overall protein structure, wild-type and chimeric gp120 
was evaluated for conformational integrity.  This was done in the context of ELISA 
by assessing their ability to bind monoclonal antibodies directed towards known 
discontinuous epitopes.  Treated 96-well plates were coated with 4 μg/mL gp120 
overnight at 4 °C in a carbonate-bicarbonate buffer (pH 8.5).  Plates were then 
washed thrice with PBS (0.05% Tween20) and the remaining uncoated surfaces 
blocked with 200 µL PBS (5% milk) for one hour at 37 °C.  All subsequent reaction 
steps were conducted in 100 µL reaction volumes at 37 °C, and preceded by an 
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identical PBS (0.05% Tween20) wash step.  First, plates were incubated with serial 
dilutions of monoclonal antibodies at concentrations between 10 µg/mL and 128 
pg/mL.  As a positive control the HIV-1 positive serum sample BB105 was used at 1 
in 5 serial dilutions starting at 1:100.  For the second and third steps plates were 
incubated first with 166.67 ng/mL biotin labelled, anti-human, goat polyclonal sera 
(KPL, Gaithersburg, U.S.A.), and then with 500 ng/mL anti-biotin, goat polyclonal 
HRP-conjugates (Calbiochem, Darmstadt, Germany).  Finally plates were incubated 
at room temperature with 100 µL volumes of the 1-Step™ Ultra TMB-ELISA 
(3,3',5,5'-tetramethylbenzidine) substrate from Thermo Scientific for approximately 
three minutes and the resulting colour reaction stopped with 25 µL of 1M H2SO4 and 
read at 450 nm on a VersaMax Tunable Microplate Reader (Molecular Devices, 
Sunnyvale U.S.A.).   
Adsorption of monomer-specific serum antibodies 
Recombinant gp120 was coated in 400 µg batches to 200 μL of MyOne™ 
tosylactivated Dynabeads® from Invitrogen as per the manufacturer’s 
recommendations.  A covalent interaction between the magnetic beads and gp120 
monomers provides a stable complex that can then be used to bind out gp120 specific 
antibodies.  All prior and subsequent incubation periods were carried out at 37 °C 
with continuous rotary motion to prevent clumping.  Beads coated with gp120 and 
blocked with BSA were washed thrice with 1 mL serum-free DMEM to remove all 
previous buffers, and then divided into two equal volumes.  The first of these was re-
suspended in 200 µL of the relevant serum sample diluted between 1:20 and 1:150 
depending on the expected titres.  After one hour incubation the adsorbed serum was 
recovered and used to re-suspend the second volume of gp120 coated beads.  
Following this the adsorbed serum was again recovered and separated from any 
remaining matrix particles by centrifugation.  The supernatant was stored at 4 °C for 
use in downstream applications.  The adsorbed sera was assayed for the successful 
depletion of binding antibodies by ELISA (as described above).  A drop in 
absorbance values when compared to serum adsorbed only with blank beads 
(negative control) correlated with the adsorption of gp120 specific antibodies (Figure 
11A).  The depletion of neutralising antibodies was measured by a neutralisation 
assay (as described below).  Again, a drop in neutralisation titres when compared to 
the negative control was a result of neutralising antibody depletion (Figure 11B).   
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Figure 11: Mock adsorption data 
(A) Mock ELISA results from an adsorption experiment.  Serum/plasma adsorbed with blank beads 
only is coloured black, while serum adsorbed with recombinant gp120 is coloured grey.  Adsorption of 
gp120 binding antibodies results in a reduced OD.  (B) Mock results for a neutralisation assay using 
serum/plasma from an adsorption experiment.  The graph is coloured as in (A).  Adsorption of gp120-
specific neutralising antibodies results in a drop in the neutralisation titre (measured as ID50).   
 
Neutralisation assay 
Neutralisation was measured in a single round of infection assay that allows for the 
assessment of antibody mediated inhibition of viral entry into host cells.  This 
neutralisation assay was adapted from the previously described method (Montefiori, 
2009).  Briefly, monoclonal antibodies or serum/plasma samples were serially diluted 
down a 96-well plate, and co-incubated in a total volume of 100 μL for one hour at 37 
°C with pseudovirus at a concentration previously determined to yield 40 000 relative 
light units (RLU).  To this 50 μL of TZM-bl cells were added to a final concentration 
of 10 000 cells per well, and incubated for 48 hours at 37 °C (5% CO2).  Following 
the two day incubation period cells were digested in the Luciferase Assay Buffer and 
resulting RLUs measured in the VICTOR
3™ Multilabel Counter as described above.  
To save on sample the assay was adapted such that diluted antibody/serum, virus, and 
TZM-bl cells were co-cultured in a total of 70 μL per well reducing the amount of 
gp120 adsorbed serum input required.  A feeding step twenty four hours post-
infection (adding 130 μL), and a reduction in the volume of cell culture media 
removed (100 μL) at forty eight hours post-infection (prior to the addition of the 
luciferin containing buffer) was also included.   
 33 
Chapter Three: Results 
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Optimisation of polyethyleneimine based transfection system 
Genes can be delivered into eukaryotic cells using a variety of tools from retroviruses 
to liposomal reagents and cationic lipids or polymers (Bonetta, 2005).  The latter are 
often incorporated into commercial chemical transfection reagents, and act as a bridge 
allowing foreign DNA to associate with the cell membrane.  Polyethyleneimine (PEI) 
has been previously described as a vehicle for gene delivery (Boussif et al., 1995).  It 
is also significantly more economical when compared to commercially available 
transfection reagents (Kirschner et al., 2006).   
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Figure 12: A comparison of PEI and Fugene
®
6 as gene delivery reagents 
ELISA data showing the relative gp120 expression levels of 293T cells transfected with different ratios 
of either PEI or FuGENE
®
6.  Optical Density readouts were compared to a standard curve of known 
gp120 concentrations serially diluted 1 in 4 from 40 μg to 2.44 ng.  The relative amount of gp120 
produced for each transfection ratio used is shown.   
 
 
Table 2: Quantity of gp120 produced 
Fugene
®
6 1 μg DNA : 1.5 μL Fugene®6 450 ng/mL 
 1 μg DNA : 3 μL Fugene®6 7 500 ng/mL 
 1 μg DNA : 6 μL Fugene®6 17 100 ng/mL 
Polyethyleneimine 1 μg DNA : 1.5 μg Polyethyleneimine 30 ng/mL 
 1 μg DNA : 3 μg Polyethyleneimine 1 500 ng/mL 
 1 μg DNA : 6 μg Polyethyleneimine 1 300 ng/mL 
 1 μg DNA 0 ng/mL 
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To reduce the cost of recombinant gp120 expression for this study a 
polyethyleneimine based transfection system was explored.  We evaluated the effect 
of different PEI : DNA ratios on recombinant gp120 expression levels, and compared 
the data to the yields obtained with FuGENE
®
6, the commercial transfection reagent 
traditionally used in our laboratory for gene delivery in a ratio of 3 μL FuGENE®6 : 1 
μg DNA.  The level of gp120 produced after transfection was quantified by ELISA 
(Figure 12).  A standard curve was constructed by capturing previously expressed 
recombinant gp120 of known concentrations onto the ELISA plate.  Transfection 
without a transfection reagent (DNA only) was included as a negative control.  As 
expected the transfection with DNA only did not produce any detectable levels of 
gp120 expression.  The level of expression increased significantly by increasing the 
ratio of FuGENE
®
6 : DNA, and similarly decreased dramatically when decreasing 
this ratio (Table 2).  A ratio of 3 μg PEI : 1 μg DNA was found to be optimal, and 
produced significantly more protein than the lower 1.5 μL FuGENE®6 : 1 μg DNA 
ratio.  Using more PEI did not significantly enhance the transfection efficiency.  Thus 
the PEI : DNA transfection ratio of 3 : 1 was shown to be a far more economical 
alternative for protein expression when compared to the FuGENE
®
6 expression 
system previously used, and was adopted for the remainder of the study.   
 
Qualitative analysis of purified recombinant gp120  
This research project required expression of sixteen different recombinant gp120 
molecules derived from four distinct viral isolates, their chimeras, and mutants.  Each 
protein was isolated from cell culture media to an estimated 91.7% ± 3.7% purity, as 
measured with the Bio-Rad Molecular Imaging® Chemi Doc XRS™ (Figure 13).  
The transfection efficacy of 293T cells using PEI was inconsistent within the context 
of the same envelope construct, but certain gp120 expression constructs (and in 
particular HIV-1CAP63 derived gp120) consistently produced less protein.  Poor gp120 
expression correlated with less efficient purification.  This was attributed to increased 
carryover of glycosylated FBS proteins that then saturated the ion exchange column, 
contaminating gp120 collected in the flow through.  The HIV-1CAP63-88(C3-V4)-63 
derived gp120 was least pure, but produced the best adsorption data from this study 
(Figure 20, discussed below).   Therefore we reason that the level of purity obtained 
for all recombinant gp120s was sufficient for the purposes of these adsorption studies.   
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Figure 13: Purity of recombinant gp120 produced in this study 
Coomasie blue stained SDS-PAGE showing eight of the sixteen recombinant proteins produced in this 
study.  The relative purity of each protein was calculated as a percentage of the total protein content in 
each lane using Quantity One software.   
 
 
As a result of the primers used to amplify the recombinant gp120 molecules, each of 
the recombinant proteins had a common N-terminal and common C-terminal 
sequence including a histidine tag (T
499
KSKRRVVESEK
510
GGSHHHHHH
519
).  A 
full sequence alignment of the parental recombinant gp120s used in this study is 
shown in Figure 14.  These polyhistidine tags provide a large, flexible surface distinct 
from biologically relevant sites on monomeric gp120.  At high pH histidine 
deprotonates to become available for coupling to the tosyl activated beads used in the 
downstream adsorption studies.  Despite the insertion of heterologous sequence into 
the protein termini, recombinant gp120 proteins produced in this study were able to 
bind monoclonal antibodies that recognise discontinuous, conformationally dependent 
epitopes (Figure 15).  Antibodies b12 and b6 contact the CD4 binding site (Pantophlet 
et al., 2003), A32 recognises a discontinuous epitope in C1-C2-C4 (Boots et al., 
1997), and 2G12 binds a unique glycan epitope (Scanlan et al., 2002).  In support of 
these data the recently published crystal structure of a liganded gp120 core with full 
N- and C- terminal domains showed that resides 40-497 are responsible for intra-
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monomer interactions, and variation outside of these residues (residues 1-39 and 487-
511) in all probability do not impact on the protein’s overall conformation (Pancera et 
al., 2010a).  Since the CD4 binding site overlaps the C3 region and the base of V5, it 
was expected that the binding of monoclonal antibodies b12 and b6 to gp120 
chimeric for the C3 and/or V5 regions would differ from the binding to parental 
gp120 molecules.  This was indeed the case for these CD4 binding site antibodies 
(Figure 15).  In some instances these differences could be explained by previous work 
that had mapped the binding site of these two antibodies.  Position 471 in the HIV-
1CAP84 backbone is occupied by an alanine, while in HIV-1CAP45 this residue is a 
glycine (Figure 14).  Alanine scanning mutagenesis has shown that anything bulkier 
than a glycine at this position significantly inhibits the binding of b12, while the more 
common glycine residue is less favourable for b6 interactions (Pantophlet et al., 
2003).  This provides some explanation as to why b12 (Figure 15, yellow line) does 
not bind well to the HIV-1CAP84 parental gp120 or chimeric gp120 with the HIV-
1CAP84 backbone, while b6 (Figure 15, purple line) binds very well to these proteins.  
Furthermore the T467I mutation in V5 significantly affects b6 binding, explaining 
differences in the binding of this antibody to the V5 chimeras.   
 
Asp
368
 is part of the CD4 binding loop and critical to HIV-1 entry.  Substitution of 
this residue with an arginine abolishes binding to CD4 as well as most anti-CD4 
binding site antibodies, including b6 and b12 (Li et al., 2007).  As seen in Figure 14, 
b12 and b6 were unable to bind the three recombinant gp120s with this mutation.  
The antibody 2G12 is subtype B specific and unable to neutralise the viruses used in 
this study.  The binding to 2G12 detected by ELISA may have resulted from low 
affinity interactions with high mannose structures contributing to the 2G12 epitope, or 
with another binding site for 2G12 formed by alternate gp120 processing.  Such 
binding sites have already been described for gp160 (Crooks et al., 2011).  As the 
A32 epitope does not involve variable residues in C3, V4, or V5, the ability of this 
antibody to bind all of the chimeric gp120s resembled binding to the parental gp120 
proteins from which the backbone was derived.  Pooled HIV-1 positive plasma (such 
as BB105) contains gp120 specific cross-reactive antibodies (such as anti-V3 
antibodies) and was used in all ELISAs as a positive control.  Overall, binding of 
these monoclonal antibodies to at least one discontinuous epitope on each 
recombinant protein confirmed proper folding of all gp120s expressed in this study.   
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Figure 14: Sequence alignment of the four parental recombinant gp120 proteins used in this study 
Sequences were aligned with the HIV-1HXB2 gp120 sequence.  Residues making up the variable loops V1-V5 are boxed in pink, purple, red, green, and blue respectively.  The 
C3 region is boxed in orange and the α2-helix, β14-sheet, β24-sheet, and CD4 binding loop are highlighted.  The β14 and flanking region described later is highlighted in cyan.  
Dots indicate amino acids identical to the HIV-1HXB2 sequence, while the ~ symbol is used when an amino acid is missing from one of the five sequences shown.   
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Adsorption of neutralisation activity by autologous gp120 
CAP88 
Previous studies in our laboratory showed that the plasma from participant CAP88 
taken at 26 weeks post-infection contained anti-C3 autologous neutralising antibodies 
(Moore et al., 2009).  At this time point the anti-C3 antibodies had reached peak titres 
while a second response targeting the V1-V2 region had just begun to appear (Figure 
16A).  This latter response went on to peak at 81 weeks post-infection.  At 54 weeks 
post-infection the declining anti-C3 response and the increasing anti-V1-V2 antibodies 
were at approximately identical titres.  In this study we showed that using magnetic 
beads coated with HIV-1CAP88 derived monomeric gp120 it was possible to completely 
adsorb all gp120 specific antibodies from plasma taken at 26 weeks post-infection, as 
measured by ELISA (Figure 16B).  The removal of these gp120 binding antibodies 
resulted in the complete depletion of autologous neutralising antibodies from this 
plasma sample (Figure 16C).  Therefore we can conclude that all the neutralising 
antibodies in this plasma sample targeted epitopes apparent on monomeric gp120.   
 
These same HIV-1CAP88 gp120 coated magnetic beads were then used to adsorb all of 
the gp120 specific antibodies from plasma taken at 54 weeks post-infection (Figure 
16D).  By depleting these antibodies it was possible to significantly decrease the ID50 
value from a titre of 1:1025 to a titre of 1:200, effectively reducing the neutralisation 
titres by 81% (Figure 16E).  The residual neutralisation activity not adsorbed by 
monomeric gp120 at this later time point might be due to the antibodies in this sample 
that target the V1-V2 loop.  Anti-V1-V2 neutralising antibodies isolated to date 
typically recognise epitopes only present on the native trimer, and cannot be adsorbed 
out of sera/plasma samples using monomeric gp120 (Kimura et al., 2009; Walker et al., 
2009).  It has been speculated that these antibodies may bind epitopes that link long 
flexible loop components of adjacent monomers (such as V2 and V3), or that the V1-V2 
loop domain simply does not adopt its native conformation in the context of monomeric 
gp120 (Walker et al., 2009).   
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Figure 16: Adsorption of CAP88 antibodies using monomeric g120 
(A) Development of neutralising antibody titres in CAP88 over time (modified from (Moore et al., 2009).  
Titres against the autologous HIV-1CAP88 and heterologous HIV-1CAP63 are shown in yellow and blue 
respectively.  Titres against chimeric viruses incorporating autologous C3, C3-V4 or V1-V2 regions are 
shown in orange, green, and purple respectively.  The two time points (26 and 54 weeks post infection) 
used for the adsorption studies are indicated with the dotted lines.  (B) Adsorption of CAP88 gp120 
binding antibodies at 26 weeks post infection measured by ELISA.  Plasma adsorbed with blank beads or 
autologous gp120 coated beads are shown in grey and yellow, while untreated plasma is shown in black.  
A reduction in the OD at 450 nm correlates with adsorption of gp120 specific antibodies.  (C) Complete 
adsorption of CAP88 neutralising antibodies from 26 weeks post-infection, coloured as in (B).  A 
reduction in ID50 and loss of neutralisation activity (indicated with the red arrow) correlates with the 
adsorption of neutralising antibodies (D) Adsorption of CAP88 gp120 binding antibodies at 54 weeks 
post-infection, coloured as in (B).   (E) Partial adsorption of CAP88 neutralising antibodies from 54 
weeks post-infection, coloured as in (B).   
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CAP45 
Preceding studies have also shown that neutralisation titres in participant CAP45 
plasma peak at 43 weeks post-infection (Moore et al., 2009).  This coincided with peak 
neutralisation titres against chimeras carrying either autologous C3-V4 or V1-V2 
regions (Figure 17A).  Magnetic beads coated with HIV-1CAP45 recombinant gp120 
were also able to adsorb out all the CAP45 gp120 binding antibodies from this time 
point (Figure 17B), resulting in a concurrent 68% ± 8% drop in the neutralisation titres 
at this time point (Figure 17C) as calculated by the reduction in ID50.  It was 
hypothesised that similarly to the CAP88 adsorption experiment, incomplete adsorption 
of CAP45 neutralisation titres using monomeric gp120 was a consequence of anti-V1-
V2 antibodies that require the native envelope quaternary structure.   
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Figure 17: Adsorption of CAP45 antibodies using monomeric g120 
(A) The development of CAP45 neutralising antibody titres over time (Moore et al., 2009).  Titres against 
the autologous HIV-1CAP45 and heterologous HIV-1CAP84 are shown in yellow and blue respectively.  
Titres against chimeric viruses incorporating autologous C3-V4 or V1-V2 regions are shown in green and 
purple respectively.  The time point used for the adsorption studies is indicated with the dotted line.  (B) 
Adsorption of CAP45 gp120 binding antibodies measured by ELISA.  Plasma adsorbed with blank beads 
or autologous gp120 coated beads are shown in grey and yellow, while untreated plasma is shown in 
black.  (C) Partial adsorption of CAP45 neutralising antibodies from 43 weeks post-infection, coloured as 
in (B).  The reduction in neutralising activity is indicated with the red arrow.   
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CAP84 
The development of autologous neutralising antibodies in CAP84 has not been as 
extensively mapped as it has with CAP88 and CAP45, making it difficult to pinpoint 
the time post infection at which anti-C3-V4 antibody titres had peaked.  Previous data 
suggested the presence of antibodies in CAP84 serum targeting the HIV-1CAP84 C3-V4 
and V5 regions (Figure 18A), with titres for both antibody specificities peaking at 37 
weeks post-infection, and remaining fairly constant through to 54 weeks post-infection 
(Moore et al., 2008).  Therefore both these time points were chosen for the adsorption 
studies.  Using magnetic beads coated with monomeric gp120 derived from HIV-1CAP84 
it was possible to adsorb almost all the binding antibodies detectable by ELISA at both 
37 weeks (Figure 18B) and 54 weeks (Figure 18D) post-infection. Similarly, 
recombinant gp120 was able to adsorb out all the neutralising antibodies in both these 
serum samples (Figures 18C and 18E) with the level of depletion similar irrespective of 
the time point used.  Given the proximity of the V5 loop to C3-V4 it is possible that 
these two specificities are related, or perhaps even the same epitope.  As shown by the 
dotted green curve in Figure 18A, removal of the autologous C3 region (the reverse 
chimera) impacted negatively on the titres of both these antibody specificities, 
suggesting that they are dependent on the C3 region (Moore et al., 2008).  Nevertheless 
the results of these adsorption studies suggest that both these antibody responses 
(whether related or not) target epitopes that were apparent on monomeric gp120.   
CAP63 
Unfortunately CAP63 progressed to AIDS very rapidly, making extensive mapping 
impossible.  Despite this earlier studies have shown that antibodies targeting the HIV-
1CAP63 C3-V4 region were present at peak titres from 20 through to 37 weeks post-
infection (Moore et al., 2008).  A portion of this activity appeared directed towards the 
V4 alone, as the HIV-1CAP88-63(V4)-88 chimera was also sensitive to CAP63 antibodies 
(Figure 19A).  Removal of the autologous C3-V4 region or the autologous V4 alone 
(reverse chimeras) had similar effects on autologous neutralisation titres.  This data 
suggests that the C3 and V4 alone do not entirely encompass this particular epitope, or 
that another neutralisation specificity began to appear simultaneously alongside the anti-
C3-V4 response.  Using magnetic beads coated with monomeric gp120 derived from 
HIV-1CAP63 almost all the gp120 binding antibodies in CAP63 serum from 20 weeks 
(Figure 19B) and 37 weeks post infection (Figure 19D) could be adsorbed out.   
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Figure 18: Adsorption of CAP84 antibodies using monomeric gp120 
(A) The development of CAP84 neutralising antibody titres over time (modified from (Moore et al., 
2009).  Titres against the autologous HIV-1CAP84 and heterologous HIV-1CAP45 are shown in yellow and 
blue respectively.  Titres against chimeric viruses incorporating autologous C3-V4 or V5 regions are 
shown in green and black respectively.  Titres against the reverse chimera incorporating a heterologous 
C3 region are shown with the dotted green line.  The time points used for the adsorption studies are 
indicated with the dotted grey (37 weeks) and black (54 weeks) lines.  (B) Adsorption of CAP84 gp120 
binding antibodies from 37 weeks post-infection, measured by ELISA.  Plasma adsorbed with blank 
beads or autologous gp120 coated beads are shown in grey and yellow, while untreated plasma is shown 
in black.  (C) Adsorption of CAP84 neutralising antibodies from 37 weeks post-infection, coloured as in 
(B).  The reduction in neutralising activity is indicated with the red arrow.  (D) Adsorption of CAP84 
gp120 binding antibodies from 54 weeks post-infection as measured by ELISA, coloured as in (B).  (E) 
Adsorption of CAP84 neutralising antibodies from 54 weeks post-infection, coloured as in (B).  The 
reduction in neutralising activity is indicated.   
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By adsorbing these antibodies it was possible to deplete 50% ± 7% of the neutralisation 
titres at both 25 weeks (Figure 19C) and 37 weeks (Figure 19E) post-infection.  The 
level of depletion was similar irrespective of the time point used.  Despite the drop in 
ID50 titres (from ~1:5500 to ~1:2750) the partial depletion of neutralisation activity does 
not reflect in the neutralisation curves, which are plotted on a log scale.  There was also 
a minor adsorption of antibodies using blank beads only (negative control) relative to 
the unadsorbed serum sample in this and subsequent experiments.  This was attributed 
to the incomplete inactivation of free tosyl groups when the beads were ‘blocked’ with 
BSA, or some level of non-specific binding of serum antibodies to the BSA coated 
beads.   
 
In summary, the autologous neutralising activities in plasma/serum from each of the 
four participants could be depleted to varying degrees using monomeric gp120.  All the 
neutralisation activity in CAP88 plasma (within the first 6 months of infection) and 
CAP84 sera was directed towards epitopes contained entirely within monomeric gp120.  
However, adsorption of a later plasma sample from CAP88 resulted in only partial 
adsorption of the total neutralisation activity.  This coincided with the development of 
anti-V1-V2 antibodies.  Since all known anti-V1-V2 antibodies target quaternary 
epitopes it is most probable that these CAP88 antibodies could not be adsorbed by 
gp120, and were responsible for the residual neutralisation activity.  Similarly the 
neutralisation activity in CAP45 sera could not be completely adsorbed with monomeric 
gp120, and this was also attributed to anti-V1-V2 antibodies that developed alongside 
the C3-V4 antibody response.  Although CAP63 ID50 titres dropped following 
adsorption with monomeric gp120, the serum samples still retained considerable 
neutralisation potency.  As was the case with CAP45 and the later sample from CAP88 
it is possible that the residual neutralisation activity in the gp120 depleted serum was 
the result of a trimer specific antibody outside of C3-V4.  However it may also be 
possible that the CAP63 C3-V4 epitope was one that requires the native trimer, or is not 
well reconstituted in the context of monomeric gp120 and could thus not be properly 
adsorbed.  To confirm that the neutralising antibodies adsorbed by monomeric gp120 
are in fact targeting the C3-V4 region, gp120s chimeric for each of the four C3-V4 
regions were expressed for adsorption studies.  The adsorbed sera were then assayed 
against the chimeric viruses to verify that each of the C3-V4 epitopes were in fact 
apparent on a single gp120 monomer.   
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Figure 19: Adsorption of CAP63 antibodies using monomeric gp120 
(A) The development of CAP63 neutralising antibody titres over time (Moore et al., 2009).  Titres against 
the autologous HIV-1CAP63 and heterologous HIV-1CAP88 are shown in yellow and blue respectively, while 
titres against chimeric viruses incorporating autologous C3-V4 or V4 regions are shown in green or black 
respectively.  Titres against the reverse chimeras, incorporating either a heterologous C3-V4 or V4 
region, are shown with the dotted green and black lines.  The time points used for the adsorption studies 
are indicated.  (B) Adsorption of CAP63 gp120 binding antibodies at 25 weeks post-infection measured 
by ELISA.  Plasma adsorbed with blank beads or autologous gp120 coated beads are shown in grey and 
yellow, while untreated plasma is shown in black.  (C) Adsorption of CAP63 neutralising antibodies from 
25 weeks post-infection, coloured as in (B).  The reduction in CAP63 neutralisation titres is indicated 
with the red arrow.  (D) Adsorption of CAP63 gp120 binding antibodies at 37 weeks post-infection 
measured by ELISA, coloured as in (B).  (E) Adsorption of CAP63 neutralising antibodies from 37 
weeks post-infection, coloured as in (B).  The reduction in CAP63 neutralisation titres is indicated.   
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CAP88 neutralising antibodies can be entirely adsorbed with the C3 
region of gp120 
Of the four participants with neutralising antibodies targeting C3-V4, the CAP88 
response was unique in that it did not require the autologous V4 for efficient 
neutralisation (Moore et al., 2008).  Rather, the variable component of this epitope 
appeared to be contained almost entirely within the C3 region (Figure 16A).  Escape 
from these antibodies was mediated entirely by two mutations in the α2-helix (Moore et 
al., 2009).  Although one change resulted in the addition of a glycan which might alter 
glycan packing and sterically occlude more distant epitopes, the second mutation 
resulted in a charge change at a solvent exposed surface, suggesting that the α2-helix 
was in fact the antibody target (Figure 8).  For the purposes of this study gp120s from 
the chimeric pseudoviruses HIV-1CAP63-88(C3-V4)-63 and HIV-1CAP63-88(C3)-63 were assessed 
for their ability to adsorb out the neutralising antibodies in CAP88 plasma from 26 
weeks post-infection.  Heterologous gp120 from the resistant HIV-1CAP63 virus that was 
used to make the backbone was also expressed and served as a negative control.   
 
Both autologous and heterologous parental gp120s, as well as both the C3 and C3-V4 
chimeric gp120 proteins were able to adsorb out all of the cross-reactive binding 
antibodies in CAP88 plasma capable of binding HIV-1CAP63 derived heterologous gp120 
in ELISA (Figure 20A).  These cross-reactive antibodies are non-neutralising and likely 
recognise conserved epitopes such as those in V3 or the CD4 binding site.  However, 
the heterologous HIV-1CAP63 gp120 was unable to significantly deplete the binding 
signal generated in ELISA against any of the other gp120s (Figures 20B, 20C, and 20D 
- blue line).  This was explained by the inability of the heterologous gp120 to adsorb out 
any of the HIV-1CAP88 specific autologous binding antibodies, such as the C3-V4 
neutralising antibodies.  While both chimeric proteins could completely adsorb out the 
binding antibodies specific for the C3 and C3-V4 chimeras (Figures 20B - orange line, 
and 20C - green line), they could both only partially deplete the binding signal 
generated against the autologous gp120 (Figure 20D - orange and green lines).  This 
residual signal could be attributed to other autologous binding antibodies in CAP88 
serum specific to epitopes outside the C3-V4 region.  These antibodies would have to 
be non-neutralising (discussed below), and probably recognise epitopes that overlap 
with other variable regions such as V1-V2.   
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Figure 20: Adsorption of CAP88 antibodies using chimeric gp120 proteins 
CAP88 plasma from 26 weeks post-infection was adsorbed with blank uncoated beads (grey), 
heterologous HIV-1CAP63 gp120 (blue), autologous HIV-1CAP88 gp120 (yellow), and chimeric gp120 from 
HIV-1CAP63-88(C3)-63 (orange) or HIV-1CAP63-88(C3-V4)-63 (green), and then compared to the unadsorbed plasma 
sample (black).  Adsorbed plasma samples were tested by ELISA for binding to (A) heterologous gp120, 
(B) C3 chimeric gp120, (C) C3-V4 chimeric gp120, and (D) autologous gp120.  They were also tested for 
their residual neutralisation activities against both the (E) HIV-1CAP63-88(C3-V4)-63 chimeric virus, and the (F) 
autologous HIV-1CAP88 virus.   
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While the heterologous gp120 could not absorb any of the neutralising antibodies in 
CAP88 serum (Figures 20E, and 20F - blue line), both the autologous (yellow line) and 
C3-V4 chimeric (orange line) gp120 proteins were able to completely deplete the 
CAP88 serum sample of its neutralising activity against both C3-V4 chimeric (Figure 
20E) and autologous (Figure 20F) viruses.  The C3 protein was slightly less efficient at 
adsorbing out these neutralising antibodies, but nevertheless was still able to drop the 
ID50 titres against both the wild-type and chimeric viruses by 84.1% and 94.8% 
respectively.  Thus it appears that access or binding to the CAP88 C3 epitope is 
influenced to some extent by the adjacent V4 loop.  Since all of the neutralising activity 
targeting the C3-V4 chimeric virus could be adsorbed by the autologous and C3-V4 
chimeric proteins, the CAP88 C3-V4 epitope must be apparent on monomeric gp120.  
Furthermore since the C3-V4 chimeric gp120 could adsorb out all of the autologous 
neutralising antibodies in CAP88 plasma at 26 weeks post infection, this region must 
serve as the sole neutralisation target at this particular time point.   
C3-V4 antibodies were completely adsorbed with monomeric gp120 
C3-V4 chimeric gp120s from the remaining three viruses (HIV-1CAP45, HIV-1CAP84, and 
HIV-1CAP63) were also assessed for the ability to adsorb out autologous neutralising 
antibodies.  Heterologous gp120s from the resistant viruses were again used as negative 
controls.   In all three experiments the binding ELISA data showed a similar pattern as 
the CAP88 data discussed above.  All recombinant proteins were able to successfully 
deplete out the cross-reactive binding antibodies in serum samples from CAP45 (Figure 
21A), CAP63 (Figure 21B), and CAP84 (Figure 21C), while only the chimeric and 
autologous proteins were able to deplete the C3-V4 specific binding antibodies in these 
same samples (Figures 21D, 21E, and 21F - green and yellow lines).  It was solely the 
autologous gp120s that were able to efficiently deplete all the autologous binding 
antibodies (Figures 21G, 21H, and 21I - yellow lines).   
 
Despite these similarities when compared to the adsorption of CAP88 binding 
antibodies, there were considerable differences when comparing the adsorption of 
CAP45, CAP63, and CAP84 specific neutralising antibodies to the CAP88 experiment 
(Figure 22).  In these three individuals the C3-V4 specific neutralising antibodies could 
again be completely adsorbed with autologous and chimeric gp120, as was evident 
when testing the adsorbed samples against the C3-V4 chimeric viruses (Figures 22A, 
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22B, and 22C - green and yellow lines).  However unlike the CAP88 adsorption 
experiment, the chimeric proteins did not adsorb any neutralisation activity when 
assayed against the parental viruses (Figures 22D, 22E, and 22F - green lines).  Thus the 
complete adsorption of the C3-V4 responses had no effect on the adsorption of 
autologous neutralisation activity in these three individuals.  This might suggest the 
presence of other antibody specificities that prevented complete adsorption of 
autologous neutralisation.  Similarly inclusion of the autologous C3-V4 may have 
rendered the chimeric pseudoviruses sensitive to only a subset of the neutralising 
antibodies targeting C3, with other antibodies in the samples targeting epitopes 
overlapping C3 but requiring other components of the envelope adjacent to C3, such as 
the V5 loop.  Lastly it is possible that the C3-V4 antibodies do not contribute at all to 
autologous neutralisation.  Therefore to attempt to explain this data, a second set of 
mutant/chimeric viruses and recombinant proteins was engineered.   
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Figure 21: ELISA data showing the adsorption of CAP45, CAP63, and CAP84 binding antibodies 
using monomeric gp120 
Adsorption of binding antibodies from CAP45 serum taken at 43 weeks post-infection (boxed in pink), 
CAP63 serum taken at 37 weeks post-infection (boxed in yellow), and CAP84 serum taken at 37 weeks 
post-infection (boxed in green), as measured by ELISA against heterologous gp120 (A, B, and C), C3-
V4 chimeric gp120 (D, E, and F), or autologous gp120 (G, H, and I).  Each serum sample was adsorbed 
with either autologous gp120 (yellow), chimeric gp120 (green), or heterologous gp120 (blue), and 
compared to unadsorbed serum (black) and serum adsorbed with blank beads only (grey).   
 
 51 
 
 
10 100 1000 10000 100000
0
25
50
75
100
HIV-1CAP84
HIV-1CAP45  gp120
HIV-1CAP84-45(C3-V4)-84  gp120
HIV-1CAP84  gp120
Blank beads
Unadsorbed serum
Serum Dilution
%
 I
n
h
ib
it
io
n
10 100 1000 10000 100000
0
25
50
75
100
HIV-1CAP63
Serum Dilution
%
 I
n
h
ib
it
io
n
HIV-1CAP45  gp120
HIV-1CAP84-45(C3-V4)-84  gp120
HIV-1CAP84  gp120
Blank beads
Unadsorbed serum
10 100 1000 10000 100000
0
25
50
75
100
HIV-1CAP84-45(C3-V4)-84
Serum Dilution
%
 I
n
h
ib
it
io
n
10 100 1000 10000 100000
0
25
50
75
100
HIV-1CAP88-63(C3-V4)-88
Serum Dilution
%
 I
n
h
ib
it
io
n
10 100 1000 10000 100000
0
25
50
75
100
HIV-1CAP45-84(C3-V4)-45
Serum Dilution
%
 I
n
h
ib
it
io
n
10 100 1000 10000 100000
0
25
50
75
100
HIV-1CAP45
Serum Dilution
%
 I
n
h
ib
it
io
n
HIV-1 CAP45  gp120
HIV-1 CAP84-45(C3-V4)-84  gp120
HIV-1 CAP84  gp120
Blank beads
Unadsorbed serum
A D
B E
C F
C
A
P
8
4
 S
e
ru
m
C
A
P
6
3
 S
e
ru
m
C
A
P
4
5
 S
e
ru
m
C
A
P
8
4
 S
e
ru
m
C
A
P
6
3
 S
e
ru
m
C
A
P
4
5
 S
e
ru
m
Figure 22: Adsorption of C3-V4 specific neutralising antibodies from participants CAP45, 
CAP63, and CAP84 
Monomeric gp120 was used to adsorb out the neutralising activity in serum samples from CAP45 taken 
at 43 weeks post-infection (boxed in pink), CAP63 taken at 37 weeks post-infection (boxed in 
yellow), and CAP84 taken at 37 weeks post-infection (boxed in green).  The adsorbed material was 
assayed against either the C3-V4 chimeric viruses (A, B, and C) or the autologous viruses (D, E, and F) 
for residual neutralisation activity.  Serum was adsorbed with either autologous gp120 (yellow), 
chimeric gp120 (green), or heterologous gp120 (blue), and compared to unadsorbed serum (black) and 
serum adsorbed with blank beads only (grey).  The neutralisation activities adsorbed with the chimeric 
gp120s are indicated with the red arrows.   
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C3-V4 chimeric envelope glycoproteins may expose epitopes in 
the CD4 binding site 
When CAP84 serum was adsorbed using magnetic beads coated with monomeric 
gp120 it was discovered that heterologous gp120 was able to adsorb out the antibodies 
in CAP84 serum responsible for the neutralisation of the chimeric virus HIV-1CAP45-
84(C3-V4)-45 (Figure 22C).  Despite this, both heterologous and chimeric gp120 could not 
adsorb any of the CAP84 autologous neutralising antibodies (Figure 22F).  This data 
might be explained if the HIV-1CAP45-84(C3-V4)-45 chimeric viruses adopted a more 
exposed conformation, rendering certain epitopes for normally non-neutralising 
antibodies more accessible on the native trimer.  The exposed epitope would have to 
be one that is common to both autologous and heterologous gp120.  This implicated 
the functionally conserved receptor binding sites, which are accessible on the native 
trimer, and partly overlap with the C3 region of the envelope.  To test whether the 
receptor binding sites had become exposed to CAP84 non-neutralising antibodies on 
the chimeric viral envelope, both parental and chimeric viruses were tested against a 
range of monoclonal antibodies (Figure 24).   
 
Only monoclonal antibodies with detectable binding to gp120 from the viruses 
concerned were used for the neutralisation experiments (Figure 15 and Figure 23).  
17b and 1.9E were the only co-receptor binding site antibodies able to bind all three 
gp120 proteins tested, and only when incubated in the presence of sCD4 (Figure 23).  
Therefore in order to neutralise viruses using co-receptor binding site directed 
antibodies, viruses were first pre-incubated for one hour at 37 °C with sCD4 at a 
concentration previously determined to inhibit viral entry by 40%.  None of the anti-
co-receptor binding site antibodies were able to neutralise either parental or chimeric 
viruses in the presence of soluble CD4 (Figure 24A).  Similarly the normally non-
neutralising anti-CD4 binding site antibody b6 could not neutralise any of these 
viruses (Figure 24B).  It was particularly significant though, that the chimeric 
pseudovirus was 2-20 fold more sensitive to neutralisation by CD4-IgG2 (IC50 of 0.22 
μg/mL) than the parental viruses HIV-1CAP45 and HIV-1CAP84 (IC50s of 0.41 μg/mL 
and 4.63 μg/mL respectively).  CD4-IgG2 is a fusion protein combining the Fc 
immunoglobulin domain with the two most terminal domains of CD4.  It was perhaps 
even more striking that the chimeric virus was neutralised at relatively low 
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concentrations of soluble CD4 (9.55 μg/mL).  The highly neutralisation sensitive T-
cell laboratory adapted strain HIV-1SF162 was used as a positive control, and was 
sensitive to neutralisation by all co-receptor and CD4 binding site antibodies tested.  
Based on these data it was concluded that the HIV-1CAP45-84(C3-V4)-45 chimeric 
pseudovirus had a more exposed CD4 binding site.  To confirm whether this exposure 
was responsible for the neutralisation of the chimeric virus by CAP84 serum, a 
D368R mutation was introduced into the parental and chimeric recombinant gp120s 
(Figure 25).  This mutation is positioned in the CD4 binding loop of C3 and is known 
to abrogate the binding of CD4 resulting in a non-functional virion.  Furthermore 
since anti-CD4 binding site antibodies typically interact with the CD4 binding loop, 
the D368R mutation also abrogates the binding of most anti-CD4 binding site 
antibodies (Li et al., 2007).   
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Figure 23: Binding of monoclonal antibodies to the co-receptor binding site is sCD4 dependent 
(A) Monomeric gp120 from HIV-1CAP45, HIV-1CAP84, and the chimeric virus HIV-1CAP45-84(C3-V4)-45 was 
tested for binding to antibodies m9 (red), 1.9E (green), and 17b (brown).  (B) The experiment shown in 
(A) was repeated in the presence of saturating concentrations of sCD4.   
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Figure 24: Exposure of the CD4 binding site in a C3-V4 chimeric virus leads to enhanced neutralisation by CD4-IgG2 and sCD4 
(A) Neutralisation of HIV-1CAP45, HIV-1CAP84, and the chimeric virus HIV-1CAP45-84(C3-V4)-45 using monoclonal antibodies 17b (brown), and 1.9E (green) in the presence of 
sCD4.  (B) Neutralisation HIV-1CAP45, HIV-1CAP84, and the chimeric virus HIV-1CAP45-84(C3-V4)-45 using soluble CD4 (cyan), and monoclonal antibodies b12 (yellow), b6 
(purple), and CD4-IgG2 (blue) with epitopes in the CD4 binding site.   
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Figure 25: Poor adsorption of anti-C3-V4 antibodies in CAP84 serum by monomeric gp120 
containing the D368R mutation 
CAP84 serum was adsorbed with wild-type gp120s (solid lines) as well as the D368R mutant gp120s 
(dotted lines) from heterologous HIV-1CAP45 (blue), autologous HIV-1CAP84 (yellow), and the C3-V4 
chimeric virus HIV-1CAP45-84(C3-V4)-45 (green).  Residual binding antibodies were detected in ELISA 
against either (A) heterologous gp120 with the D368R mutation, (B), heterologous gp120 (C), C3-V4 
chimeric gp120 with the D368R mutation (D) C3-V4 chimeric gp120, and (E) autologous gp120.  
Adsorbed sera tested for the ability to neutralise both the (F) autologous and (G) C3-V4 chimeric 
pseudoviruses.   
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Recombinant gp120s derived from HIV-1CAP45 or HIV-1CAP45-84(C3-V4)-45 carrying the 
D368R mutation were able to efficiently adsorb out all the binding antibodies specific 
for the mutant proteins (Figures 25A and 25B - dotted blue and green lines), but this 
adsorption did not affect the binding signal generated against the parental (Figures 
25C and 25E) and chimeric (Figure 25D) proteins in ELISA.  Thus despite the 
adsorption of all gp120 binding antibodies not affected by the D368R mutation, a 
saturating ELISA signal was still generated to the wild-type proteins from exclusively 
anti-CD4 binding site antibodies.  Conversely autologous gp120 derived from HIV-
1CAP84 with the D368R mutation was able to completely adsorb out all the gp120 
binding antibodies in CAP84 serum (Figures 25C, 25D, and 25E - dotted yellow line).   
 
Similarly while serum adsorbed with the heterologous HIV-1CAP45 gp120 and 
chimeric HIV-1CAP45-84(C3-V4)-45 gp120 depleted all of the neutralisation activity against 
the HIV-1CAP45-84(C3-V4)-45 chimeric virus (Figure 25G - solid green and blue lines), 
when the D368R mutation was introduced into these two proteins they were no longer 
able to adsorb out this activity (Figure 25G - dotted green and blue lines).  Since the 
only difference between the serum adsorbed with either wild-type gp120s or mutant 
gp120s was the absence or presence of anti-CD4 binding site antibodies, these 
antibodies must be responsible for the neutralisation of the C3-V4 chimeric virus.  
Consistent with the ELISA data HIV-1CAP84 autologous gp120 with the D368R 
mutation retained the ability to deplete the anti-CD4 binding site antibodies 
responsible for the neutralisation of HIV-1CAP45-84(C3-V4)-45, and was just as efficient as 
the wild-type autologous protein at adsorbing the neutralising antibodies specific for 
HIV-1CAP84 (Figures 25F and 25G - yellow lines).  Thus neutralisation of the C3-V4 
chimera is mediated by antibodies to the CD4 binding loop, but these antibodies can 
still be adsorbed by autologous gp120 with the D368R mutation.  Therefore it must be 
concluded that these antibodies bind significantly to other surrounding residues in the 
autologous protein that are not present in the heterologous gp120.   
CAP45 antibodies target an epitope in β14+V5 that is apparent on 
monomeric gp120 
Adsorption of CAP45 antibodies targeting C3-V4 did not affect autologous 
neutralisation titres, but adsorption of all gp120 binding antibodies partially depleted 
this activity.  To explain this data a more detailed map of the antibody specificities in 
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CAP45 serum within the first year of infection was constructed.  The viral quasi-
species in participant CAP45 showed very little envelope sequence variability (Moore 
et al., 2009).  In fact after one year of infection there were only eight amino acid 
substitutions that were positively selected for across the whole of HIV-1CAP45 gp160 
(Appendix B).  Of these mutations, three in V1-V2 have been shown to correlate with 
escape from V1-V2 directed antibodies, while an additional two in V5 were shown to 
mediate escape from a potent neutralising antibody with an unknown specificity, 
presumed to be related to the anti-C3-V4 response (Moore et al., 2009).  Transferring 
the HIV-1CAP45 V5 into the resistant HIV-1CAP84 heterologous backbone did not confer 
neutralisation sensitivity to participant CAP45’s neutralising antibodies (Moore et al., 
2008).  The remaining three mutations were in C1, V3, and V4 and had no effect on 
neutralisation sensitivity when back mutated in the 12 month clone (Moore et al., 
2009).  To attempt an explanation of the neutralisation escape mediated by the two V5 
mutations, and potentially account for the escape from anti-C3-V4 antibodies, we 
created a chimera incorporating the autologous C3 and V5 regions (HIV-1CAP84-
45(C3+V5)-84) and assessed its sensitivity to neutralisation by CAP45 serum.  The 
resulting chimera generated neutralisation titres that were consistently lower when 
compared to the wild-type virus, but showed a distinctly similar pattern over time 
(Figure 26 - red line).  This was in contrast to the C3-V4 chimera which showed titres 
similar to the V1-V2 chimera (Moore et al., 2009).   A C3+V5 chimeric gp120 was 
then generated for adsorption studies.  Given the saturating levels of neutralisation 
despite a 1 in 20 dilution of CAP45 serum in the C3-V4 adsorption experiments, the 
serum was diluted further to 1:150 for the C3+V5 adsorption studies.  Adsorption of 
binding antibodies by the C3+V5 chimeric protein was similar to that of the C3-V4 
chimeric protein in that it was able to deplete out all the cross-reactive and C3+V5 
binding antibodies specific for the chimeric protein, but could not deplete out all of 
the autologous binding antibodies in CAP45 serum (Figures 21, 27A and 27B).  
However distinct differences were apparent in the ability of the C3+V5 chimeric 
gp120 to adsorb out the CAP45 autologous neutralising antibodies.   
 
In addition to adsorbing out all the C3+V5 specific antibodies responsible for 
neutralising HIV-1CAP84-45(C3+V5)-84 (Figure 27C – red line), the C3+V5 chimeric gp120 
was also able to adsorb some of the autologous neutralising antibodies (Figures 27D - 
red line), something the C3-V4 chimeric gp120 was unable to achieve (Figure 22).  
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However the C3+V5 chimeric gp120 could not deplete any of the neutralising 
antibodies targeting the C3-V4 chimeric pseudovirus HIV-1CAP84-45(C3-V4)-84 and vice 
versa, suggesting that these two epitopes are distinct from each other on monomeric 
gp120 (Figures 27C - green line, and 27E - red line).  Furthermore the autologous 
gp120 and the C3+V5 chimeric gp120, but not the C3-V4 chimeric gp120 were also 
able to deplete out all of the neutralisation activity targeting the twelve month clone 
with the two back-mutations in V5 (HIV-1CAP45.52wks.07 V5(E460K/G426D)) implicating 
these mutations in mediating escape from the C3+V5 specific antibodies but not C3-
V4 specific antibodies (Figure 27F).  To further define the C3+V5 neutralisation 
epitope we constructed a chimera containing the autologous V5, as well the 
autologous β14 and flanking regions (highlighted in cyan in Figure 3).  Neutralisation 
titres against this chimera closely matched the titres against the C3+V5 chimeric 
pseudovirus, with minor differences possibly being explained by an improper 
conformation of the epitope in the context of β14+V5 only, or a diverse B-cell 
response to the C3+V5 epitope (Figure 26 - grey line).  Thus, the C3+V5 epitope was 
further defined as an epitope in β14+V5, immediately adjacent to the CD4 binding 
site.  Since the β14+V5 epitope overlaps the CD4 binding site, it is possible that 
antibodies targeting this site are reliant on residues in the CD4 binding loop.  To 
determine whether this was the case we attempted to adsorb out CAP45 anti-β14+V5 
antibodies using autologous HIV-1CAP45 gp120 with and without the D368R mutation 
(Figure 28).  Both these proteins were able to adsorb out the CAP45 neutralising 
antibodies to similar extent, indicating that anti-β14+V5 antibodies were not sensitive 
to the D368R mutation (comparison of the solid and dotted yellow lines).   
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Figure 26: Development of anti-β14+V5 neutralising antibodies in CAP45 serum 
The neutralisation titres in CAP45 serum was plotted at each time point against either the autologous 
virus (yellow), heterologous virus (blue), C3+V5 chimeric virus (red), or β14+V5 chimeric virus (dark 
grey filled in pink).   
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Figure 27: Adsorption of C3+V5 neutralising antibodies using monomeric gp120 
CAP45 serum was adsorbed with either blank beads (grey), autologous gp120 (yellow), heterologous 
gp120 (blue), C3-V4 chimeric gp120 (green), or C3+V5 chimeric gp120 (red), and compared to 
unadsorbed serum (black).  Adsorption of binding antibodies to either the (A) C3+V5 chimeric protein, 
or (B) autologous protein was assessed by ELISA.  Adsorbed serum was tested for residual 
neutralisation activity against either the: (C) C3+V5 chimeric virus, (D) infecting autologous virus, (E) 
C3-V4 chimeric virus, or (F) autologous virus isolated from twelve months post-infection with back-
mutations in two residues in V5 (E460K/G462D).   
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Figure 28: The β14+V5 epitope is distinct from the CD4 binding site epitope 
Adsorption of participant CAP45 serum antibodies from 43 weeks post-infection using autologous 
gp120 with either the wild-type aspartic acid or mutant arginine amino acid at position 368 (colouring 
is the same as in Figure 22).   
 
 
In summary, a third target for neutralising antibodies in CAP45 sera was identified, 
the titres of which peaked at roughly the same time as the previously identified C3-V4 
and V1-V2 antibody specificities.  This third group of antibodies targeted an epitope 
made up of the juxtaposed β14 sheet (in C3) and V5 loop, adjacent to the CD4 
binding site.  Furthermore all of the neutralisation activity directed towards this region 
could be completely adsorbed with monomeric gp120.  The complete adsorption of 
these antibodies had a significant effect on autologous neutralisation titres, but did not 
account for all the neutralisation activity in the CAP45 sample.  Two mutations in V5 
previously identified as conferring escape from CAP45 sera were shown to mediate 
sensitivity to these antibodies.  However this antibody specificity was distinct from 
the previously identified anti-C3-V4 response to which the V5 mutations were 
thought to have been produced.  Since the only other mutations previously shown to 
mediate escape from CAP45 antibodies were in V1-V2, we attempted to use V1-
V2+C3-V4 chimeric virions to determine whether V1-V2 escape mutations were 
responsible for mediating escape from anti-C3-V4 neutralising antibodies.   
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Mutations in V1 mediate escape from antibodies with epitopes in 
C3-V4 
Apart from the two mutations in V5 that have now been shown to confer resistance to 
CAP45 autologous neutralising antibodies targeting the HIV-1CAP45 β14+V5 region, 
only three other mutations have previously been shown to affect neutralisation 
sensitivity to CAP45 sera.  Two of these changes were in V2 while a third was in V1 
(Moore et al., 2009).  To determine whether these mutations were responsible for 
conferring resistance to the CAP45 anti-V1-V2 antibodies they were introduced into 
the HIV-1CAP84-45(V1-V2)-84 heterologous chimera (Figure 29A - dotted lines).  
Introduction of the V1 associated S139N mutation, which shifts a potential N-linked 
glycosylation site by two amino acids, failed to confer any neutralisation resistance to 
antibodies targeting the V1-V2 region (dotted grey line).  Conversely introduction of 
the two V2 associated mutations (K186R/G190aE) conferred complete resistance to 
these antibodies (dotted brown line).  It has been shown previously that the HIV-
1CAP45.52wks.c07 V1(N139S) back mutant (which inherently has both V2 associated escape 
mutations) was still sensitive to earlier CAP45 serum antibodies (Moore et al., 2009).  
Therefore this data suggested that the S139N mutation in V1 mediates escape from 
antibodies targeting epitopes outside of V1-V2.   
 
To examine whether the V1 associated mutation conferred resistance to CAP45 
antibodies targeting the C3-V4 region we created pseudoviruses chimeric for both the 
C3-V4 and V1-V2 regions (HIV-1CAP84-45(V1-V2+C3-V4)-84), and assessed their 
neutralisation sensitivity to CAP45 sera.  Titres against the V1-V2+C3-V4 (Figure 
29B - pink line) chimera were greater than those against either the C3-V4 (Figure 29B 
- green line) or V1-V2 (Figure 29A - purple line) chimeric viruses alone, compatible 
with an accumulation of these two neutralisation specificities.  Interestingly 
introduction of the S139N mutation into the V1-V2+C3-V4 chimeric virus dropped 
these neutralisation titres to a magnitude similar to the titres generated against the 
HIV-1CAP45.52wks.c07 V2(R186K/E190aG) back mutant (Figure 29B - dotted grey line).  By 
introducing both V1 and V2 associated changes into the V1-V2+C3-V4 heterologous 
chimera these titres dropped even further, becoming almost negligible (Figure 29B - 
dotted black line).  Cumulatively this data suggested that the S139N mutation was 
involved in mediating escape from anti-C3-V4 autologous neutralising antibodies.  
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Although the V1-V2 stem exists in a region distinct from C3-V4, the structure of the 
V1-V2 domain has not yet been resolved.  Repositioning of a large glycan structure at 
position 139 may thus serve to sterically occlude C3-V4 epitopes, possibly by 
influencing the overall conformation of V1-V2 or glycan packing in the context of the 
native trimer.  In support of this data it has recently been shown that two glycans in 
the V2 region confer resistance to neutralisation by b12, an anti-CD4 binding site 
antibody with an epitope overlapping the C3 region (Utachee et al., 2010; Wu et al., 
2009).   
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Figure 29: Escape mutations in V1-V2 potentially affect the C3-V4 epitope 
Longitudinal development of CAP45 neutralisation specificities and the concurrent development of 
HIV-1CAP45 escape mutations in V1-V2 with time.  Titres generated against the autologous HIV-1CAP45 
virus is shown in yellow.  (A) Development of titres against the wild-type V1-V2 heterologous chimera 
(purple) and mutant V1-V2 chimeras with either the S139N (dark grey) or K186R/G190aE escape 
mutations (brown) are shown.  (B) Development of titres against the wild-type C3-V4 (green) or V1-
V2+C3-V4 (pink) chimeric viruses, and mutant V1-V2+C3-V4 chimeras with either the S139N (dark 
grey) or S139N/K186R/G190aE (black) escape mutations are shown.   
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Complete escape from neutralising antibodies does not correlate 
with complete loss of binding 
The introduction of two mutations into the α2-helix of HIV-1CAP88 (I339N/E350K) 
rendered the virus completely resistant to anti-C3 autologous neutralising antibodies 
(Moore et al., 2009).  Similarly the introduction of two mutations in the V5 loop of 
HIV-1CAP45 (K460E/D462G) conferred complete resistance to neutralisation by an 
antibody that recognises a discontinuous epitope in β14 and V5.  However the 
mechanism through which HIV-1 is able to escape these antibodies has yet to be 
elucidated.  To this end recombinant gp120 proteins incorporating the described 
escape mutations were expressed for subsequent adsorption experiments (Figures 30 
and 31).  Mutant gp120s were assessed for the ability to adsorb out neutralising 
antibodies in CAP88 plasma from twenty six weeks post-infection and CAP45 serum 
from forty three weeks post-infection, when compared with the wild-type autologous 
gp120s.  In both instances although the escaped gp120s were able to adsorb out all the 
binding antibodies specific for the escaped proteins (Figures 30A and 31A - dotted 
lines), they were unable to completely deplete the signal generated by autologous 
antibodies recognising the wild-type proteins (Figures 30B and 31B - dotted lines).  
The residual signal generated by antibodies that could not be adsorbed by the mutant 
gp120s must therefore be the result of epitopes directly affected by these escape 
mutations.   
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Figure 30: CAP88 anti-C3 antibodies bind to escaped gp120 
CAP88 plasma from 26 weeks post-infection was adsorbed with either blank beads (grey), beads 
coated with autologous gp120 (yellow), or beads coated with autologous gp120 containing the escape 
mutations I339N and E343K (peach), and compared with unadsorbed plasma (black).  Adsorbed 
plasma was assayed for residual binding antibodies to either (A) escaped gp120, or (B) wild-type 
autologous gp120, as well as (C) residual autologous neutralising antibodies against HIV-1CAP88.   
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As expected HIV-1CAP88 gp120 with the escape mutations I339N and E343K could 
not deplete the autologous neutralisation activity in CAP88 plasma to the extent that 
wild-type gp120 could (Figure 30C - dotted line). Nevertheless it was still able to 
partially deplete some of these anti-C3 neutralising antibodies.  Similarly, although 
HIV-1CAP45 gp120 with the escape mutations K460E and D462G was also unable to 
adsorb out the autologous neutralising antibodies to the degree that the wild-type 
protein could, it was still able to significantly deplete the neutralisation activity in 
CAP45 serum (Figure 31C).  This partial adsorption of autologous neutralisation by 
gp120 carrying the K460E and D462G mutations may be explained by adsorption of 
CAP45 antibodies targeting the C3-V4 epitope.  To rule out this particular scenario, 
the ability of escaped HIV-1CAP45 gp120 to deplete exclusively anti-C3+V5 titres was 
measured by assessing the ability of mutant gp120 to deplete the antibodies 
responsible for the neutralisation of the HIV-1CAP84-45(C3+V5)-84 chimeric and HIV-
1CAP45.52wks.c07(E460K/G462D) back mutated viruses  Again the mutant gp120 was able to 
partially deplete the neutralising activity against these two viruses (Figures 31D and 
31E).  Thus although mutations in the α2-helix of HIV-1CAP88 and the V5 loop of 
HIV-1CAP45 mediate complete escape from neutralising antibodies, they do not 
completely abrogate the ability of these antibodies to bind their respective epitopes.   
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Figure 31: CAP45 anti-C3+V5 antibodies bind to escaped gp120 
CAP45 serum from 43 weeks post-infection was adsorbed with blank beads (grey), wild-type 
autologous gp120 (dark pink), or escaped mutant gp120 (light pink), and compared to unadsorbed 
serum (black).  Adsorbed sera was assayed for residual binding antibodies to either (A) escaped gp120, 
or (B) wild-type autologous gp120, as well as residual autologous neutralising antibodies against either 
(C) HIV-1CAP45, (D) HIV-1CAP45.52wks.c07(E460K/G462D), or (E) HIV-1CAP84-45(C3+V5)-84.   
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Chapter Four: Discussion 
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With respect to the native envelope trimer the HIV-1 gp120 monomer is the most well 
understood component of the viral infection machinery.  Given the ever increasing 
wealth of knowledge on the structure of this glycoprotein and its interactions with 
broadly neutralising antibodies, it represents the best starting point for the rational 
design of an HIV-1 vaccine.  To understand exactly how this building block needs to 
be manipulated into an effective immunogen will require an in depth understanding of 
the types of immunodominant epitopes contained within its structure.  This study has 
conclusively shown that the newly discovered C3-V4 epitope is one that is contained 
in its entirety on monomeric gp120, and thus represents an important aspect of gp120 
antigenicity to consider during immunogen development.   
 
After it was originally identified as a complex discontinuous epitope, anti-C3-V4 
antibodies were found in four individuals from the CAPRISA cohort (Moore et al., 
2008).  The region was identified as a neutralisation target through the use of chimeric 
viruses.  This approach has in the past been shown to have its caveats, for instance 
transplanting the V1-V2 region from one virus to another has been shown to modulate 
the exposure of distal epitopes in gp120 and gp41, rendering the chimeric viruses 
sensitive to normally non-neutralising antibodies (Ching and Stamatatos, 2010; Pinter 
et al., 2004).  If binding antibodies are present in the study sample with epitopes that 
are normally occluded on the native trimer, but become more accessible in the context 
of a chimeric envelope, then those antibodies will have the ability to potently 
neutralise the chimeric virus, but not either of the parental strains.  It has been shown 
previously that most HIV infected individuals develop non-neutralising antibodies to 
epitopes in the receptor binding sites (Gray et al., 2009).  The use of C3-V4 chimeras 
in previous studies was justified by the fact that these chimeric viruses remained 
resistant to heterologous serum from multiple individuals (Moore et al., 2008).  Data 
from this study showed that transplanting the C3-V4 region may expose epitopes in 
the CD4 binding site not normally accessible on the native trimer.  However, although 
the HIV-1CAP45-84(C3-V4)-45 chimeric pseudovirus had a more exposed CD4 binding 
site, it did not become universally sensitive to all non-neutralising antibodies targeting 
the CD4 binding site.  Rather, it gained sensitivity to exclusively the CAP84 
antibodies.  The fact that autologous HIV-1CAP84 gp120 with the D368R mutation was 
still able to deplete the CAP84 anti-CD4 binding site antibodies suggests that while 
neutralisation of the chimera was mediated by conserved elements in the CD4 binding 
 67 
loop, the antibodies were also dependent on isolate specific residues in more variable 
regions.  CAP84 developed an anti-V5 neutralisation response that coincided with the 
development of anti-C3-V4 antibodies (Moore et al., 2008).  Furthermore all the 
neutralisation activity in CAP84 serum within the first year of infection was entirely 
reliant on an autologous C3 region.  Given the juxtaposition of the V5 and C3-V4 
regions it is plausible that these two responses are in fact one in the same.  Potentially 
by adopting a slightly more exposed conformation the C3-V4 chimeric pseudovirus 
indirectly acquired neutralisation sensitivity to the CAP84 autologous neutralising 
antibodies.  Such antibodies might recognise a conserved element in the CD4 binding 
loop and variable components in the immediately adjacent C3 and/or V4 regions 
transferred to the chimera, as well as the other variable residues in the V5 loop 
(Figure 32D).  Rather than wholly exposing the CD4 binding site to a myriad of cross-
reactive antibodies, it seems that this chimera exposed an epitope only partially in the 
CD4 binding site but still for the most part reliant on exposed variable regions 
normally accessible to neutralising antibodies.   
 
This study showed that a discontinuous epitope in the C3+V5 regions (and more 
specifically the β14+V5 regions) is exposed on the viral trimer and serves as a 
potential target for autologous neutralising antibodies.  This epitope is apparent on 
monomeric gp120 and lies adjacent to the conserved CD4 binding site.  While the 
CD4 binding site is protected from neutralising antibodies by entropic masking and 
occlusion by glycans and/or V1-V2, the initial site of CD4 attachment must remain 
constant on the outer domain to facilitate efficient recognition of the host receptor.  
Antibodies that bind to this site in the outer domain do not need to suffer the large 
entropic penalties of binding normally induced after CD4 docking (Kwong et al., 
2002).  Indeed it is this accessible site of initial CD4 attachment that has been 
identified as a potential vaccine target (Figure 32).  The broadly neutralising antibody 
b12 binds to this epitope (Figure 32B), and isothermal titration calorimetry data has 
implicated the newly discovered VRC03 antibody in recognising this same epitope 
(Wu et al., 2010).  Both these antibodies are significantly affected by the D368R 
mutation, which abrogates their binding to monomeric gp120.  Conversely, while both 
the CAP45 and CAP84 antibodies appear to target an epitope that overlaps with the 
CD4 binding site (and possibly the CD4 binding loop), their binding to autologous 
gp120 was unaffected by the D368R mutation.   
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Figure 32: C3+V5 epitopes overlap with epitopes of known broadly neutralising antibodies 
targeting the CD4 binding site 
Ribbon diagrams of gp120 coloured grey.  The surface areas contacted by (A) CD4, (B) b12, and (C) 
VRC01are shown.  (D) The surface area of gp120 potentially recognised by anti-C3+V5 antibodies.  
The β14 sheet and adjoining areas are coloured purple, while the V5 loop and CD4 binding loop are 
coloured blue and orange respectively.  Structures were created in Pymol from the pdb files 2B4C and 
3JWD.   
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No doubt it is this reliance on adjacent variable structures that greatly limits the 
neutralisation breadth of these antibodies.  Thus it seems by placing a small but highly 
immunogenic variable loop structure such as V5 immediately adjacent to the recessed 
CD4 binding site, the HIV-1 envelope is able to avoid a broadly cross-reactive B-cell 
response by redirecting antibody paratopes to less essential regions.  However, the V5 
loop is also an important component of the binding site for the most potent and 
broadly cross-reactive neutralising antibodies discovered to date, VRC01 and VRC02.  
Of the 11 amino acids that make up the V5 loop and adjoining β24 sheet, eight are 
contacted by VCR01 (Figure 32C) through direct interaction with both main chain 
and side chain atoms (Zhou et al., 2010).  The C3+V5 epitope may be seen as the 
enemy, one that distracts the immune system from developing broad and potent 
neutralising antibodies.  However in the context of affinity maturation the C3+V5 
epitope may actually be seen as a fortuitous gift to the vaccine developer, an 
immunogenic epitope adjacent to the CD4 binding site containing elements in both 
V5 and C3 that may initiate a B-cell response with the potential to mature and 
develop broad cross-reactivity such as that exhibited by antibodies VRC01 and b12 
(Figure 32D).  A greater understanding of the frequency and nature of β14+V5 or 
related epitopes, and their relationship with later cross-neutralising antibodies should 
significantly aid in the development of a vaccine immunogen able to elicit a broadly 
neutralising antibody response to the CD4 binding site.   
 
The contribution of the C3-V4 response in CAP45 serum is harder to elucidate.  
Removal of C3-V4 binding antibodies did not impact at all on the overall autologous 
neutralisation titres.  This may result from the contemporaneous existence of other 
neutralising antibodies with epitopes in C3+V5 and V1-V2, the combined titres of 
which have a potency of neutralisation equal to the unadsorbed serum sample.  It was 
originally thought that given their position relative to C3-V4 two mutations in V5 
conferred neutralisation resistance to the C3-V4 epitope.  Here it was shown that these 
mutations resulted in viral escape from antibodies recognising an epitope in β14+V5.  
While two escape mutations in V2 confer complete resistance to antibodies targeting 
V1-V2, it appears the relocation of a glycosylation site by two amino acids in V1 
confers resistance to the C3-V4 neutralisation epitope.  As a direct result of the 
extremely dense glycosylation sequon clustering of HIV-1, often a potential N-linked 
glycosylation site is not utilised because of the steric interference from a neighbouring 
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glycan.  The down regulation of one site by another is particularly significant when 
the sequons are separated by five or less amino acids (Poon et al., 2007).  In the 
context of the HIV-1CAP45 V1 loop the glycan implicated in escape moves from 
position 137 to position 139.  This shifts it to a more favourable position for actual N-
linked glycosylation between the more conserved V1 flanking glycans at position 133 
and 146 (Figure 33A).  Thus the S139N mutation may actually result in the 
acquisition of a glycan (rather than the repositioning of one) which is sterically 
constrained enough to provide the escape for an epitope in the distant C3-V4 region.  
As has been documented by the non-neutralising antibody b13 and the broadly 
neutralising antibody b12, which recognise almost identical overlapping epitopes in 
the CD4 binding site, the precise angle of antibody binding to its antigen is a critical 
determinant of its ability to neutralise (Chen et al., 2009).  Resistance to the b12 
antibody can be conferred by introducing a glycosylation site into V2 at position 197 
or position 186, potentially occluding the angle of approach for b12 (Wu et al., 2009).  
The observation that the accessibility of epitopes in C3-V4 might actually be 
restricted by glycans in V1-V2 is an important consideration when constructing C3-
V4 heterologous chimeras in future instances.  The HIV-1CAP84 V1-V2 domain is 
equivalent in length to the HIV-1CAP45 V1-V2 domain, and the V1 loop differs in 
sequence by less than 30% with a very similar glycosylation pattern.  This allowed for 
the acquisition of neutralisation sensitivity by the C3-V4 chimera despite the presence 
of a heterologous V1-V2 loop (Figure 33B).   
 
HIV-1CAP45 V1:
HIV-1CAP84 V1:
Asn133 Asn137 Asn146
Asn133 Asn137 Asn146
Asn133 Asn139 Asn146
 
Figure 33: Glycosylation pattern of the HIV-1CAP45 and HIV-1CAP84 V1 loops 
(A) The wild type sequence for the HIV-1CAP45 V1 loop is shown on top, while the escaped sequence 
including the S139N mutations is shown at the bottom.  Potential N-linked glycosylation sites are 
indicated.  The glycosylation sequon at position 137 proposed to be under negative selection is shown 
with faded colours.  (B) The HIV-1 CAP84 V1 loop sequence is shown and annotated as in (A).   
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The CAP63 C3-V4 response is as equally puzzling as the CAP45 C3-V4 response in 
that adsorption of these antibodies also failed to impact on autologous neutralisation 
titres.  Furthermore despite the fact that all the C3-V4 responses were apparent on 
monomeric gp120, it appears the HIV-1CAP63 C3-V4 epitope was not as well adsorbed 
by monomeric gp120.  Partial transfer of neutralisation sensitivity could be obtained 
using V4 alone and so it appears that the epitope was predominantly in V4, although 
C3 was an important contributing factor.  The V4 loop is already a large plastic 
structure, and monomeric gp120 is obviously far more dynamic in solution than in the 
native trimer.  So even if this epitope was wholly contained within monomeric gp120 
it may not be well represented outside of the more conformationally constrained viral 
envelope spike.  Since complete adsorption of the C3-V4 epitope did not affect 
autologous neutralisation titres it is possible that this epitope, like the one presented in 
HIV-1CAP45-84(C3-V4)-45, is the result of an exposure of a conserved sequence motif.  
However it can also be argued that antibodies targeting the quaternary structure in the 
CAP63 sample adsorbed of its anti-gp120 activity are still able to produce an almost 
saturating neutralisation signal, as was the case with the CAP45 adsorbed sera.  From 
the limited longitudinal data available for participant CAP63, replacement of both V4 
and C3-V4 with heterologous sequence resulted in an equivalent loss in titre.  This 
loss in titre was not complete at any time point tested and suggested that as in the case 
of CAP45, a second antibody specificity in CAP63 sera developed alongside the anti-
C3-V4 antibodies.  Like the CAP45 antibodies targeting V1-V2, this second 
specificity would also target the native envelope trimer since it cannot be adsorbed by 
monomeric gp120, and as such it would be responsible for the saturating 
neutralisation signal generated by gp120 adsorbed sera.   
 
Collectively the data generated from this study cautions the use of heterologous C3-
V4 chimeric viruses to discern autologous neutralisation epitopes.  With that being 
said these chimeras can provide important clues as to the nature of neutralising 
antibody targets when taken in conjunction with longitudinal escape data.  If 
neutralisation specificities develop simultaneously and with almost identical titres in a 
single individual, this may mean that current strategies using back-mutations in 
escaped viruses could underestimate the number of antibody specificities that drive 
neutralisation escape of HIV-1 viruses during early infection.   
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Data from this and other studies on CAP88 plasma put forward a strong case for the 
presentation of the α2-helix of subtype C envelope glycoproteins as a direct target for 
autologous neutralising antibodies (Moore et al., 2009).  Adsorption data from this 
study suggests a role for V4 in this epitope.  The HIV-1CAP63 V4 loop is eight amino 
acids longer than the HIV-1CAP88 V4 loop and has a distinctly different glycosylation 
pattern (Figure 14).  It is possible that the α2-helix epitope is partially occluded by V4 
in the context of the HIV-1CAP63-88(C3)-63 C3-chimera.  Alternatively it is possible that 
these antibodies interact with atoms in the V4 loop or that binding is complemented 
by V4 specific glycans.  These potential interactions would be non-essential for 
antibody binding but may serve to fasten the antibody into place after it has docked 
with the α2-helix.  Their absence may thus promote faster complex dissociation and 
result in poor adsorption of the autologous neutralising antibodies.  Though six 
months may be limited time for antibody affinity maturation, there exists yet another 
possible explanation for the involvement of V4 in the C3 epitope.  It has become 
increasing clear as of late that one can no longer assume that a particular antibody 
response is the product of a single antibody.  The recent isolation of the potent 
neutralising antibodies PG09-PG16 and VCR01-VCR02 reveal that they exist as 
clonally related antibodies with slight differences in epitope recognition (Walker et 
al., 2009; Wu et al., 2010).  This information advocates the possibility that there are 
two or more clonally related C3-V4 directed antibodies in the CAP88 plasma sample, 
one of which is more reliant on V4 than the other.   
 
It is fascinating that neutralisation escape mutations did not correlate with complete 
loss of antibody binding.  These autologous neutralising antibodies bind epitopes that 
are accessible on monomeric gp120 even in the context of escape.  In the context of 
the native trimer the effect of escape mutations may influence intermolecular 
interactions and significantly manipulate the conformation of an adjoining 
neutralisation epitope.  Once gp120 is liberated from the native trimer its inherently 
plastic structure may still allow for proper formation of such an epitope.  Similarly the 
acquisition of glycan involved in escape from CAP88 anti-C3 antibodies and CAP45 
anti-C3-V4 antibodies may only serve to occlude the neutralisation epitopes in the 
context of the completely glycosylated native trimer.  In an alternative scenario, 
escape mutations such as those in the V5 of HIV-1CAP45 may actually lie within the 
antibody binding site.  These mutations may simply serve to lower the affinity 
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between an antibody and its antigen to a point that the binding is no longer tight 
enough to promote neutralisation of the free virion.  Given either circumstance these 
observations are of great significance in the context of vaccine design.  If antibodies 
continue to bind their respective epitopes even after viruses have escaped their 
neutralising activities, these antibodies may continue to affinity mature towards 
multiple variants of the same epitope and eventually might develop greater 
neutralisation breadth.  Alternatively these antibodies may actually exert some form 
of immune pressure on the virus such as low level neutralisation not detectable in 
current neutralisation assays, or antibody-dependent cell-mediated cytotoxicity.  
Evidence for this may exist in CAP45.  The viral population in this individual at 8 
months post infection adopted the mutations S139N, K186R and D462G, effectively 
escaping all antibodies targeting the V1-V2, C3-V4, and β14+V5 epitopes.  Yet 
despite complete escape from these antibodies, the viral population four months later 
acquires the additional escape mutations G191aE and K460E, suggesting that some 
immune pressure is still being exerted on the virus in vivo despite no detectable 
neutralisation in vitro.  By studying the evolving interactions between antibodies and 
their antigens with time it may be possible to gain exciting insight as to how an 
immune response might be guided towards the development of potent and broadly 
neutralising antibodies.  C3 related neutralisation epitopes such as those in the α2-
helix and β14+V5, together with other non-neutralising epitopes adjacent to the CD4 
binding site (such as those potentially exposed by C3-V4 chimeras), represent a major 
component of the autologous neutralising antibody response targeting monomeric 
gp120 and potentially immunogenic epitopes for a gp120 based vaccine immunogen.   
 
Autologous neutralising antibodies are far more common than broadly cross-reactive 
neutralising antibodies, and highly immunogenic strain specific epitopes overlapping 
with the CD4 binding site provide significant obstacles towards eliciting broadly 
neutralising anti-CD4 binding site antibodies.  Conversely these epitopes may also 
serve as immunogens to elicit anti-CD4 binding site precursor antibodies.  Once an 
antibody is partially reliant on the CD4 binding site, it may then be possible to affinity 
mature these antibodies to more conserved epitopes.  Such a strategy has already been 
proposed for eliciting PG09-PG16 like antibodies (Pancera et al., 2010b).  
Understanding the structure and immunogenicity of these autologous neutralisation 
epitopes and designing strategies to shift B-cell responses to more conserved epitopes 
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will contribute greatly to the rational design of a vaccine better able to elicit 
neutralising antibodies with broad cross-reactivity.  Future work will aim at isolating 
monoclonal antibodies from sequential time points in selected individuals with 
broadly cross-reactive sera, which together with contemporaneous HIV-1 envelope 
sequence data should promote a better understanding of how these type-specific 
antibodies became broadly neutralising.  Overall there has been a major shift in 
research focus of late towards isolating monoclonal antibodies to specific sites on the 
envelope.  As this study has shown, the isolation of specific monoclonal antibodies is 
greatly complicated by the diverse nature of the B-cell response within a single 
individual.  Isolating a single specificity is most economically possible with a highly 
specific reagent, such as the RSC3 protein engineered for the isolation of VRC01, 
VRC02, and VRC03 (Wu et al., 2010).  When the epitope is not known, or only 
poorly defined, the best reagent in these instances remains a gp120 monomer such as 
those used in this study.  By better understanding which antibody specificities can be 
adsorbed with monomeric gp120 and how the virus escapes from them (such as the 
data generated in this study) researchers would be better able to design more specific 
reagents for the isolation of a single B-cell response.   
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HIV-1CAP45                                                                                                             
                 MRVRGILRNWPQWWIWSILGFWMLIICRVMGNLWVTVYYGVPVWKEAKATLFCASDARAYEKEVHNVWATHACVPTDPNPQEIYLGNVTENFNMWKNDMV  
CAP45 4 months                                                                                                         
                 ...........P........................................................................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
CAP45 8 months                                                                                                         
                 .................................................P..................................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
                 .......................................................N............................................  
CAP45 12 months                                                                                                        
                 .......................................................N............................................  
                 ................G......................................N............................................  
                 .....................G...........................P..................................................  
                 .......................................................N............................................  
 
HIV-1CAP45                                                                                                             
                 DQMHEDIISLWDQSLKPCVKLTPLCVTLRCTNATINGSLTEEVKNCSFNITTELRDKKQKAYALF~YRPDVVPLNKNSPSGNSSEYILINCNTSTITQAC  
CAP45 4 months                                                                                                         
                 .................................................................~..................................  
                 .................................................................~..................................  
                 .................................................................~..................................  
CAP45 8 months                                                                                                         
                 .......................................A.........................~..................................  
                 .....................................N...........................~.........R........................  
                 .....................................N...........................~.........R........................  
                 .....................................N...........................~.........R........................  
                 .....................................N...........................~.........R........................  
                 .....................................N...........................~.........R........................  
                 .....................................N...........................~.........R........................  
                 .....................................N...........................~.........R........................  
CAP45 12 months                                                                                                        
                 .....................................N...........................~.........R....E...................  
                 .....................................N...........................~.........R....E...................  
                 .....................................N...........................~...........G......................  
                 .....................................N...........................~.........R....E...................  
 
HIV-1CAP45                                                                                                             
                 PKVSFDPIPIHYCAPAGYAILKCNNKTFNGTGPCNNVSTVQCTHGIKPVVSTQLLLNGSLAEEDIIIKSENLTNNIKTIIVHLNKSVEIVCRRPNNNTRK  
CAP45 4 months                                                                                                         
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 8 months                                                                                                         
                 ....................................................................................................  
                 ..............................................................................................S.....  
                 ..............................................................................................S.....  
                 ..............................................................................................S.....  
                 ....................................................................................................  
                 ..............................................................................................S.....  
                 ...........................................R..................................................S.....  
                 ..............................................................................................S.....  
CAP45 12 months                                                                                                        
                 ..............................................................................................S.....  
                 ..............................................................................................S.....  
                 ....................................................................................................  
                 ..............................................................................................S.....  
 
HIV-1CAP45                                                                                                             
                 SIRIGPGQAFYATNDIIGDIRQAHCNINNSTWNRTLEQIKKKLREHFLNRTIEFESPSGGDLEVTTHSFNCGGEFFYCNTTRLFKWSSNVTNDTITIPCR  
CAP45 4 months                                                                                                         
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 8 months                                                                                                         
                 ...........................S........................................................................  
                 ......................................................................................F.............  
                 ......................................................................................F.............  
                 ......................................................................................F.............  
                 ..........................................................................................A.........  
                 ......................................................................................F.............  
                 ......................................................................................F.............  
                 ......................................................................................F.............  
CAP45 12 months                                                                                                        
                 ......................................................................................F.............  
                 ......................................................................................F.............  
                 ...........................S.Y......................................................................  
                 ......................................................................................F.............  
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HIV-1CAP45                                                                                                             
                 IKQFINMWQGVGRAMYAPPIEGNITCNSSITGLLLTRDGGKTDRNDTEIFRPGGGNMKDNWRNELYKYKVVEIKPLGVAPTEARRRVVEREKRAVGIGAV  
CAP45 4 months                                                                                                         
                 ........................................~~~.........................................................  
                 ..........................................G........................C................................  
                 ..........................................G.........................................................  
CAP45 8 months                                                                                                         
                 ........................................E...........................................................  
                 ..........................................G.........................................................  
                 ..........................................G.........................................................  
                 ..........................................G...A.....................................................  
                 ..........................................G.........................................................  
                 ..........................................G...A.....................................................  
                 ..........................................G.........................................................  
                 ..........................................G.........................................................  
CAP45 12 months                                                                                                        
                 ........................................E.G.........................................................  
                 ........................................E.G.........................................................  
                 ........................................E..K..............................................G.........  
                 ........................................E.G.........................................................  
 
HIV-1CAP45                                                                                                             
                 LLGFLGAAGSTMGAASITLTVQARQLLSGIVQQQSNLLRAIEAQQHMLQLTVWGIKQLQTRVLAIERYLKDQQLLGLWGCSGKLICTTNVPWNSSWSNKS  
CAP45 4 months                                                                                                         
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 8 months                                                                                                         
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 12 months                                                                                                        
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
 
HIV-1CAP45                                                                                                             
                 QTDIWDNMTWIQWDREISNYSNTIYKLLEDSQNQQEQNEKDLLALDSWNNLWNWFNITNWLWYIKIFIMIIGGLIGLRIILGVLSIVKRVRQGYSPLSFQ  
CAP45 4 months                                                                                                         
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 8 months                                                                                                         
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 12 months                                                                                                        
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ...................................................................................F................  
 
HIV-1CAP45                                                                                                             
                 TLTPNPRGLDRLGRIEEEGGEQDKDRSIRLVNGFLALAWEDLRSLCLFSYHRLRDFILIAVRAVELLGSSSLRGLQRGWEALKYLGSLLQYWGLELKKSA  
CAP45 4 months                                                                                                         
                 ...........................V........................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 8 months                                                                                                         
                 ......................................................N.............................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
CAP45 12 months                                                                                                        
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
                 ....................................................................................................  
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HIV-1CAP45                                                       
                 INLLDTVAIAVAEGTDRIIELIQRICRAIRNIPRRIRQGFEAALL*  
CAP45 4 months                                                   
                 .............................................*  
                 .............................................*  
                 .............................................*  
CAP45 8 months                                                   
                 .............................................*  
                 .............................................*  
                 .............................................*  
                 .............................................*  
                 .............................................*  
                 .........................................P..GI  
                 .............................................*  
                 .............................................*  
CAP45 12 months                                                  
                 .............................................*  
                 ...........................................F.*  
                 ...........................................F.*  
                 ...........................................F.*  
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List of Corrections 
 
Reviewer one had no corrections for this dissertation 
 
Reviewer two – Style, Grammar, and Typographical errors 
1. A space was inserted between all numbers and their corresponding unit descriptors with the exception 
that a space was not added before the percent symbol (%) or the degree symbol (°), when the latter 
was not preceding the symbol for Celsius (C).   
2. The word “one” was deleted from the sentence.   
3. A space was inserted between “structure” and “(Ellerbrok et al., 1992)”.   
4. The sentence was altered as suggested.   
5. The sentence was altered as suggested.   
6. The sentence was changed to: “CD4 independent isolates have been isolated in vitro that 
constitutively present an exposed co-receptor binding site and are thus highly neutralisation 
sensitive”.   
7. In the figure caption for Figure 1 we state that: “Protein structure images for this and all subsequent 
figures (unless otherwise stated) were created from the superimposed pdb files 2B4C and 3JWD 
using Swiss-PdbViewer programme and Pymol”, to avoid unnecessary repetition.   
8. The sentence was altered as suggested.   
9. The sentence was altered as suggested.   
10. The sentence was altered as suggested.   
11. The sentence was altered as suggested.   
12. The sentence was altered as suggested.   
13. The sentence was altered as suggested.   
14. The sentence was altered as suggested.   
15. The sentence was altered as suggested.   
16. The sentence was altered as suggested.   
17. The sentence was altered as suggested.   
18. The sentence was altered as suggested.   
19. All figure headings were changed to the same font size.   
20. In all instances where two adjacent regions ‘x’ and ‘y’ were transferred together, this is referred to as 
‘x-y’.  Similarly in all instances where to discontinuous regions ‘x’ and ‘z’ were transferred together, 
this is referred to as ‘x+z’.  Where this was in error it was corrected accordingly.  In addition this was 
further clarified in the abbreviations section.   
21. The sentence was altered as suggested.   
22. The sentence was corrected so that it referred to Figures 22C and 22F.   
23. All graph headings were changed to boldface.   
24.  
a. The sentence was altered as suggested.   
b. All figure captions referring to the incorrect graphs were changed.   
25. The parentheses were changed to contain: “Figures 25F and 25G - yellow lines”.   
26. Corrected in point 20 (above).   
27. Any sentence include a citation was changed so that the citation appeared in parentheses at the end of 
the sentence.   
28. The sentence was altered as suggested.   
 
 
 
 
Reviewer two – Content/Technical 
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1. The reviewer was correct in noticing that histidine tags were added to the recombinant gp120 
proteins, but not used for subsequent protein purification.  These tags were in fact added to facilitate 
coupling to the magnetic beads used for the adsorption studies.  At high pH a polyhistidine tail is 
deprotonated, making it a good nucleophile.  This provides a good surface distinct from other 
biologically relevant regions on monomeric gp120 (like the receptor binding sites) for covalent 
binding to the tosyl-activated beads.  We did attempt purification with Ni-agarose matrix to make full 
use of the tags, but found this method of purification to be inferior to the lectin affinity column.   
To explain this in the dissertation the following sentence was added to page 36, paragraph 1, 
lines 5-8: “These polyhistidine tags provide a large, flexible surface distinct from biologically 
relevant sites on monomeric gp120.  At high pH histidine deprotonates to become available for 
coupling to the tosyl activated beads used in the downstream adsorption studies”.   
2. We have noted as a common trend in our laboratory that the worse our expression levels the less pure 
a final product actually is.  This is independent of the construct used.  We hypothesise the reason for 
this to be in part related to a competitive effect.  When recombinant gp120 expression is low, this 
allows for a greater number of glycosylated FBS proteins with lower affinity for the lectin affinity 
column to be adsorbed from the cell culture supernatant and eluted with gp120.  For the subsequent 
chromatographic step this mannose elution is loaded onto a Q sepharose ion exchange column, and 
purified gp120 is collected in the flow through.  If the sample contains a higher ratio of FBS proteins 
to recombinant gp120, then a larger fraction of the sample must be retained by the matrix.  As the 
column becomes more and more saturated the FBS proteins begin to compete with each other for 
binding to the matrix, and there is a greater likelihood that some proteins will escape into the flow 
through and contaminate the gp120 sample.  Some potential corrective measures may be to reduce 
the lectin column capacity, or increase the Q sepharose column capacity, but ideally this would 
require foresight as to whether or not a protein will express poorly.   
To explain this theory the following sentence was added to page 35, paragraph 2, lines 7-10: 
“Poor gp120 expression correlated with less efficient purification.  This was attributed to 
increased carryover of glycosylated FBS proteins that then saturated the ion exchange column, 
contaminating gp120 collected in the flow through”.   
3. We agree that perhaps the choice of wording here was not entirely clear  Rather than suggesting that 
binding to 2G12 was random and non-specific, we were suggesting that this binding was in fact to 
glycans but not specifically to the 2G12 epitope as it is defined in the literature.  It is possible that this 
binding is to some portion of the 2G12 epitope that exists in subtype C, but is not enough to confer 
neutralisation sensitivity.  Alternatively this binding may be explained by the formation of alternate 
binding sites for 2G12 as a product of other recombinant gp120 glycosylation pathways.  For 
instance, a variant of gp160 produced in natural infection that is glycosylated in the endoplasmic 
reticulum is covered in high mannose glycans and exhibits at least two binding sites for 2G12.   
To clarify this statement the sentence  was altered to read: “The binding to 2G12 detected by 
ELISA may have resulted from low affinity interactions with high mannose structures 
contributing to the 2G12 epitope, or with another binding site for 2G12 formed by alternate 
gp120 processing.  Such binding sites have already been described for gp160 (Crooks et al., 
2011)”.   
4. All results from the adsorptions and neutralisation assays were repeated and confirmed, however as 
there is a small degree of variation between experiments an accurate comparison can only be made 
when run in parallel with the same sample.  This is the final data that went into each of the figures 
shown.  That being said after several repeats we can say with much conviction that the differences 
observed between each assay are not significant.  In the example provided, the reviewer asks why 
binding of CAP84 serum depleted with wild-type CAP84 gp120 is consistently higher than the 
corresponding serum depleted with CAP84 (D368R), and whether or not this difference is significant.  
The answer is that this difference is very small and not significant given the variation of the 
experiment.   
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